As filed with the Securities and Exchange Commission on February 23, 2016
Registration No. 333-203292
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1
to
Form S-3
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
Regulus Therapeutics Inc.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware |
|
26-4738379 |
(State or other jurisdiction of
incorporation or organization) |
|
(IRS Employer
Identification Number) |
3545 John Hopkins Ct., Suite 210
San Diego, CA 92121
(Address, including zip code, and telephone number, including area code, of registrants principal executive offices)
Paul C. Grint, M.D.
President and Chief Executive Officer
Regulus Therapeutics Inc.
3545 John Hopkins Ct., Suite 210
San Diego, CA 92121
(858) 202-6300
(Name,
address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Thomas A. Coll, Esq.
Kenneth J. Rollins, Esq.
Cooley LLP
4401 Eastgate
Mall
San Diego, CA 92121
(858) 550-6000
Approximate
date of commencement of proposed sale to public: From time to time after the effective date of this Registration Statement.
If the
only securities being registered on this form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ¨
If any of the securities being registered on this form are to be offered on a delayed or
continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following
box. x
If this form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
If this form is a post-effective amendment filed pursuant to Rule 462(c) under the
Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
If this form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become
effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. x
If this form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register
additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):
|
|
|
|
|
|
|
Large accelerated filer |
|
¨ |
|
Accelerated filer |
|
x |
|
|
|
|
Non-accelerated filer |
|
¨ (Do not check if a smaller reporting company) |
|
Smaller reporting company |
|
¨ |
CALCULATION OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
Title of Class of
Securities to be Registered |
|
Amount
to be
Registered(1) |
|
Proposed
Maximum
Offering Price
per
Share |
|
Proposed
Maximum
Aggregate
Offering Price |
|
Amount of
Registration Fee |
Primary Offering: |
|
|
|
|
|
|
|
|
Common Stock, $0.001 par value per share |
|
$150,000,000(2) |
|
|
|
$150,000,000(3) |
|
$15,105 |
Secondary Offering: |
|
|
|
|
|
|
|
|
Common Stock, $0.001 par value per share |
|
597,833 |
|
$6.16(4) |
|
$3,682,651.28(4) |
|
$371(5) |
|
|
(1) |
Pursuant to Rule 416 under the Securities Act of 1933, as amended, or the Securities Act, the shares being registered hereunder include such indeterminate number of shares of common stock as may be issuable with respect
to the shares being registered hereunder as a result of stock splits, stock dividends or similar transactions. |
(2) |
There are being registered hereunder such indeterminate number of shares of common stock to be sold by the Registrant which have an aggregate initial offering price not to exceed $150,000,000. |
(3) |
Calculated pursuant to Rule 457(o) under the Securities Act. |
(4) |
This estimate is made pursuant to Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee. The price per share and aggregate offering price are based on the average high and low prices
reported for the Registrants common stock traded on the NASDAQ Global Market on February 16, 2016. |
(5) |
Previously paid in connection with the filing of the registration statement on Form S-3 (File No. 333-203292) being amended hereby on April 8, 2015. |
EXPLANATORY NOTE
This Post-Effective Amendment No. 1 to the Registration Statement on Form S-3 (File No. 333-203292) is being filed to include information that
is required to be included in the registration statement by such form for registrants who are no longer well-known seasoned issuers, as defined in Rule 405 under the Securities Act.
PROSPECTUS
$150,000,000
Common Stock
597,833 Shares
of Common Stock
Offered by Selling Stockholder
We may from time to time offer to sell up to $150,000,000 of our common stock pursuant to this prospectus. In addition, the selling
stockholder identified in this prospectus may sell, from time to time, up to 597,833 shares of our common stock. We will not receive any proceeds from sales by the selling stockholder.
This prospectus describes some of the general terms that may apply to an offering of our common stock. The specific terms and any other
information relating to a specific offering will be set forth in a supplement to this prospectus to the extent required by applicable law. We may also authorize one or more free writing prospectuses to be provided to you in connection with
these offerings. The prospectus supplement or free writing prospectus, as applicable, may also add, update or change information contained in this prospectus with respect to that specific offering. You should read this prospectus, the
information incorporated by reference into this prospectus and any applicable prospectus supplement or free writing prospectus carefully before you invest.
Our common stock may be offered and sold in the same offering or in separate offerings, directly by us to investors, through agents designated
from time to time or to or through underwriters or dealers, or through a combination of these methods. For additional information on the methods of sale, you should refer to the section entitled Plan of Distribution in this prospectus
and in the applicable prospectus supplement. If any agents or underwriters are involved in the sale of any common stock with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees,
commissions, discounts and options to purchase additional shares will be set forth in a prospectus supplement. The price to the public of our common stock and the net proceeds we expect to receive from such sale will also be set forth in a
prospectus supplement.
Our common stock is listed on The NASDAQ Global Market under the trading symbol RGLS. The last
reported sale price of our common stock on The NASDAQ Global Market on February 22, 2016 was $7.61 per share. You are encouraged to obtain current market quotations for shares of our common stock.
Our principal executive offices are located at 3545 John Hopkins Ct., Suite 210, San Diego, California 92121, and our telephone number at that
address is (858) 202-6300.
INVESTING IN OUR COMMON STOCK INVOLVES A HIGH DEGREE OF RISK. YOU SHOULD REVIEW CAREFULLY THE RISKS AND UNCERTAINTIES REFERENCED UNDER THE
HEADING RISK FACTORS ON PAGE 6 OF THIS PROSPECTUS AS WELL AS THOSE CONTAINED IN ANY APPLICABLE PROSPECTUS SUPPLEMENT AND ANY RELATED FREE WRITING PROSPECTUS, AND UNDER SIMILAR HEADINGS IN THE OTHER DOCUMENTS
THAT ARE INCORPORATED BY REFERENCE INTO THIS PROSPECTUS.
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
This prospectus may not be used to consummate sales of securities unless, to the extent required by applicable law, it is accompanied by a
prospectus supplement.
Prospectus dated February 23, 2016
TABLE OF CONTENTS
We have not authorized anyone to provide you with information other than the information contained in or
incorporated by reference into this prospectus or any applicable prospectus supplement or free writing prospectus that we may authorize in connection with an offering of our common stock. We are not making an offer to sell or seeking an offer to buy
shares of our common stock under this prospectus or any applicable prospectus supplement or free writing prospectus in any jurisdiction where the offer or sale is not permitted. The information contained in this prospectus, any applicable prospectus
supplement or free writing prospectus, and the documents incorporated by reference herein and therein are accurate only as of their respective dates, regardless of the time of delivery of this prospectus or any sale of a security.
ABOUT THIS PROSPECTUS
This prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or the SEC, using
the shelf registration process. Under this shelf registration process, we may offer and sell from time to time in one or more offerings the common stock described in this prospectus up to a total dollar amount of $150,000,000. In
addition, under this shelf process, the selling stockholder may sell from time to time up to 597,833 shares of our common stock.
This
prospectus provides you with a general description of our common stock that we and/or the selling stockholder may offer. Each time we and/or the selling stockholder offer shares of our common stock under this prospectus, we will provide a prospectus
supplement that will contain more specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to an offering of our common
stock. We may also add, update or change in any prospectus supplement (and in any related free writing prospectus that we may authorize to be provided to you) any of the information contained in this prospectus or in the documents that we have
incorporated by reference into this prospectus. We urge you to carefully read this prospectus, any applicable prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as described
under the headings Where You Can Find More Information and Incorporation of Certain Information Reference before buying any of the common stock being offered.
In this prospectus, unless otherwise stated or the context otherwise requires, the terms Regulus, the Company,
we, us and our refer to Regulus Therapeutics Inc. Each of the trade names or service marks appearing or incorporated by reference in this prospectus or any applicable prospectus supplement are the property of
their respective owners.
This prospectus may not be used to consummate a sale of common stock unless, to the extent required by
applicable law, it is accompanied by a prospectus supplement.
You should rely only on the information contained in, or incorporated
by reference into, this prospectus and any applicable prospectus supplement, along with the information contained in any free writing prospectuses we have authorized for use in connection with a specific offering. Neither we nor the selling
stockholder have authorized anyone to provide you with different or additional information. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus, any accompanying prospectus
supplement or in any related free writing prospectus that we may authorize to be provided to you. This prospectus is an offer to sell only the common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do
so.
The information appearing in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate
only as of the date on the front of the document and any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus, any applicable
prospectus supplement or any related free writing prospectus, or any sale of a security. Our business, financial condition, results of operations and prospects may have changed since those dates.
This prospectus contains and incorporates by reference market data and industry statistics and forecasts that are based on independent
industry publications and other publicly available information. Although we believe that these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently verified this information.
Although we are not aware of any misstatements regarding the market and industry data presented in this prospectus and the documents incorporated herein by reference, these estimates involve risks and uncertainties and are subject to change based on
various factors, including those discussed under the heading Risk Factors contained in any applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated
by reference into this prospectus. Accordingly, investors should not place undue reliance on this information.
1
This prospectus contains summaries of certain provisions contained in some of the documents
described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed
or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the section entitled Where You Can Find More
Information.
2
SUMMARY
The Company
We are a biopharmaceutical
company focused on discovering and developing first-in-class drugs that target microRNAs to treat a broad range of diseases. We were formed in 2007 when Alnylam Pharmaceuticals, Inc., or Alnylam, and Ionis Pharmaceuticals, Inc. (formerly Isis
Pharmaceuticals, Inc.), or Ionis, contributed significant intellectual property, know-how and financial and human capital to pursue the development of drugs targeting microRNAs pursuant to a license and collaboration agreement. We have
established strategic alliances with AstraZeneca AB and Sanofi to discover, develop and commercialize microRNA therapeutics. Under these strategic alliances, we are eligible to receive approximately $900.0 million in aggregate milestone
payments upon successful commercialization of microRNA therapeutics for the programs contemplated by our agreements. These payments include up to $105.3 million upon achievement of preclinical and investigational new drug, or IND, milestones,
up to $128.0 million upon achievement of clinical development milestones, up to $180.0 million upon achievement of regulatory milestones and up to $490.0 million upon achievement of commercialization milestones.
microRNAs are naturally occurring ribonucleic acid, or RNA, molecules that play a critical role in regulating key biological pathways.
Scientific research has shown that the improper balance, or dysregulation, of microRNAs is directly linked to many diseases. To date, approximately 500 microRNAs have been identified in humans, each of which is believed to interact
with a specific set of genes that control key aspects of cell biology. Since most diseases are multi-factorial and involve multiple targets in a pathway, the ability to modulate gene networks by targeting a single microRNA provides a new
therapeutic approach for treating complex diseases.
RNA plays an essential role in the process used by cells to encode and translate
genetic information from DNA to proteins. RNA is comprised of subunits called nucleotides and is synthesized from a DNA template by a process known as transcription. Transcription generates different types of RNA, including messenger RNAs that carry
the information for proteins in the sequence of their nucleotides. In contrast, microRNAs are RNAs that do not code for proteins but rather are responsible for regulating gene expression by affecting the translation of target messenger RNAs.
By interacting with many messenger RNAs, a single microRNA can regulate several genes that are instrumental for the normal function of a biological pathway.
We believe that microRNA therapeutics have the potential to become a new and major class of drugs with broad therapeutic application
for the following reasons:
|
|
|
microRNAs, until recently, have not been a focus of pharmaceutical research; |
|
|
|
microRNAs play a critical role in regulating biological pathways by controlling the translation of many target genes; |
|
|
|
microRNA therapeutics target entire disease pathways which may result in more effective treatment of complex multi- factorial diseases; and |
|
|
|
microRNA therapeutics may be synergistic with other therapies because of their different mechanism of action. |
We believe we have assembled the leading position in the microRNA field, including expertise in microRNA biology and
oligonucleotide chemistry, a broad intellectual property estate, relationships with key opinion leaders and a disciplined drug discovery and development process. We refer to these assets as our microRNA product platform. We are using our
microRNA product platform to develop chemically modified, single-stranded oligonucleotides that we call anti-miRs to modulate microRNAs and return diseased cells to their healthy state. We believe microRNAs may be transformative
in the field of drug discovery and that anti-miRs may become a new and major class of drugs with broad therapeutic application, much like small molecules,
3
biologics and monoclonal antibodies. In addition to our microRNA product platform, we have established Regulus microMarkersSM, a
division focused on identifying microRNAs as biomarkers of human disease to support our therapeutic pipeline, collaborators and strategic partners. Regulus microMarkersSM utilizes a
clinically-validated, highly reproducible technology platform to identify microRNAs as potential biomarkers for disease and we control key intellectual property and know-how related to the division. We believe that microRNA biomarkers
may be used to select optimal patient segments in clinical trials and to monitor disease progression or relapse. We believe these microRNA biomarkers can be applied toward drugs that we develop and drugs developed by other companies with
which we partner or collaborate. We have completed a research collaboration with Biogen Idec focused on the discovery of microRNAs as biomarkers for multiple sclerosis and have also completed research for another leading, commercial-stage
pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. We also maintain several academic research collaborations focused on the identification of microRNAs as biomarkers in multiple disease areas.
Corporate Information
We were
originally formed as a limited liability company under the name Regulus Therapeutics LLC in the State of Delaware in September 2007. In January 2009, we converted Regulus Therapeutics LLC to a Delaware corporation and changed our name to Regulus
Therapeutics Inc. Our principal executive offices are located at 3545 John Hopkins Court, Suite 210, San Diego, California 92121, and our telephone number is (858) 202-6300. Our corporate website address is www.regulusrx.com. Information
contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only.
We use Regulus Therapeutics as a trademark in the United States and other countries. We have filed for registration of this
trademark in the United States and have registered it in the United States, the European Union and Switzerland. We use microMarkers as a servicemark in the United States and other countries. We have filed for registration of this
servicemark in the United States. This prospectus contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork and
other visual displays, may appear without the ® or symbols, but such references are not intended to indicate, in any way, that we
will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies trade names or trademarks to imply a
relationship with, or endorsement or sponsorship of us by, any other companies.
We are an emerging growth company, as defined
in the Jumpstart Our Business Startups Act of 2012. We will remain an emerging growth company until the earlier of (a) December 31, 2017, (b) the last day of the fiscal year in which we have total annual gross revenue of at least
$1.0 billion, or (c) the last day of the fiscal year in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700.0 million as of the prior
June 30th and (d) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period. We refer to the Jumpstart Our Business Startups Act of 2012 herein as the JOBS Act, and
references herein to emerging growth company shall have the meaning associated with it in the JOBS Act.
The Securities That May Be Offered
We may offer shares of our common stock from time to time in one or more offerings under this prospectus up to a dollar amount of
$150,000,000. In addition, the selling stockholder may offer up to 597,833 shares of common stock in one or more offerings and in any combination. A prospectus supplement, which we will provide in connection with each offering, will
describe the specific amounts, prices and terms of the offering. This prospectus may not be used to consummate a sale of our common stock unless it is accompanied by a prospectus supplement.
4
Throughout this prospectus, when we refer to the shares of our common stock being registered
on behalf of the selling stockholder, we are referring to the shares of common stock that have been issued pursuant to the transactions described below. When we refer to the selling stockholder in this prospectus, we are referring to the investor in
the private placements who is named in this prospectus as the selling stockholder and, as applicable, any donees, pledgees, transferees or other successors-in-interest selling shares received after the date of this prospectus from the selling
stockholder as a gift, pledge, or other non-sale related transfer.
Private Placements
In January 2009, in connection with the conversion of Regulus Therapeutics LLC, a Delaware limited liability company, into Regulus
Therapeutics Inc., we issued an aggregate of 7,599,000 shares of series A convertible preferred stock to Ionis in exchange for the membership interests held by Ionis in Regulus Therapeutics LLC immediately prior to such conversion. In March 2009, in
connection with our series A convertible preferred stock financing, we issued and sold an aggregate of 5,000,000 shares of series A convertible preferred stock to Ionis at a purchase price of $2.00 per share, for aggregate gross proceeds of
$10.0 million. In connection with the foregoing transactions, we entered into a Founding Investor Rights Agreement with Ionis pursuant to which we granted certain registration rights to Ionis. Upon completion of our initial public offering, the
foregoing shares were converted into an aggregate of 6,299,500 shares of our common stock.
The issuances described above were exempt from
registration under the Securities Act of 1933, as amended, or the Securities Act, pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of, and Regulation D promulgated under, the
Securities Act.
5
RISK FACTORS
Investing in our common stock involves significant risks. Before making an investment decision, you should carefully consider the risks and
other information we include or incorporate by reference in this prospectus and any prospectus supplement. In particular, you should consider the risk factors under the heading Risk Factors included in our most recent Quarterly Report on
Form 10-Q, which is on file with the SEC and is incorporated herein by reference, and which may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future. The risks and uncertainties we have
described are not the only ones facing our company. Additional risks and uncertainties not currently known to us or that we currently deem immaterial may also affect our business operations. Additional risk factors may be included in a prospectus
supplement relating to a particular offering of our common stock.
SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS
This prospectus, any prospectus supplement and the documents incorporated by reference herein contain forward-looking
statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that involve substantial risks and uncertainties. All statements, other than
statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words
anticipate, believe, continue, should, estimate, expect, intend, may, plan, project, will, and similar expressions
are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements may include, but are not limited to, statements concerning the following:
|
|
|
the initiation, cost, timing, progress and results of, and our expected ability to undertake certain activities and accomplish certain goals with respect to, our research and development activities, preclinical studies
and clinical trials; |
|
|
|
our ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations, and/or warnings in the label of an approved product candidate; |
|
|
|
our ability to obtain funding for our operations; |
|
|
|
our plans to research, develop and commercialize our product candidates; |
|
|
|
our strategic alliance partners election to pursue development and commercialization; |
|
|
|
our ability to attract collaborators with development, regulatory and commercialization expertise; |
|
|
|
future activities to be undertaken by our strategic alliance partners, collaborators and other third parties; |
|
|
|
our ability to obtain and maintain intellectual property protection for our product candidates; |
|
|
|
the size and growth potential of the markets for our product candidates, and our ability to serve those markets; |
|
|
|
our ability to successfully commercialize, and our expectations regarding future therapeutic and commercial potential with respect to, our product candidates; |
|
|
|
the rate and degree of market acceptance of our product candidates; |
|
|
|
our ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; |
|
|
|
regulatory developments in the United States and foreign countries; |
|
|
|
the performance of our third-party suppliers and manufacturers; |
6
|
|
|
the success of competing therapies that are or may become available; |
|
|
|
the loss of key scientific or management personnel; |
|
|
|
our ability to successfully secure and deploy capital; |
|
|
|
our use of proceeds of any offering pursuant to this prospectus; |
|
|
|
our expectations regarding the time during which we will be an emerging growth company under the JOBS Act; and |
|
|
|
the accuracy of our estimates regarding expenses, future revenues, capital requirements and need for additional financing. |
We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue
reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary
statements included and incorporated by reference in this prospectus that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. See the section entitled Risk Factors herein
for more information. You should consider these factors and other cautionary statements made in this prospectus and in the documents we incorporate by reference as being applicable to all related forward-looking statements wherever they appear in
the prospectus and in the documents incorporated by reference. Unless specifically indicated, our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may
make. We do not assume any obligation to update any forward-looking statements.
USE OF PROCEEDS
Unless otherwise provided in any applicable prospectus supplement, we currently intend to use the net proceeds from the sale of our common
stock offered by under this prospectus for general corporate purposes, including preclinical and clinical development of our microRNA development candidates, including accelerating the investment in the development of our lead candidate
RG-101, and the identification and validation of additional microRNA targets, for our Regulus microMarkersSM division and for capital expenditures, working capital and other general
corporate purposes. We may also use a portion of the net proceeds to in-license, acquire or invest in complementary microRNA businesses, technologies, products or assets. However, we have no current commitments or obligations to do so. We may
set forth additional information on the use of proceeds from the sale of our common stock we offer under this prospectus in a prospectus supplement relating to the specific offering. We cannot currently allocate specific percentages of the net
proceeds that we may use for the purposes specified above. As a result, our management will have broad discretion in the allocation of the net proceeds. Pending their use, we plan to invest the net proceeds from this offering in short- and
intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.
We will not receive any proceeds from the sale of shares of our common stock by the selling stockholder.
DESCRIPTION OF CAPITAL STOCK
The following description of our common stock, together with any additional information we include in any applicable prospectus supplements,
summarizes the material terms and provisions of our common stock that we and/or the selling stockholder may offer under this prospectus. For the complete terms of our common stock, please refer to our certificate of incorporation and bylaws, which
are exhibits to the registration statement that includes this prospectus. The terms of our common stock may also be affected by Delaware law.
7
Authorized Capital Stock
Our certificate of incorporation currently authorizes us to issue up to 200,000,000 shares of common stock, $0.001 par value, and 10,000,000
shares of preferred stock, $0.001 par value.
As of January 31, 2016, we had 52,695,533 shares of common stock outstanding and no shares
of preferred stock outstanding. We will describe the specific terms of any common stock we and/or the selling stockholder may offer in more detail in a prospectus supplement relating to the offering of shares of common stock.
Common Stock
Voting. Our common
stock is entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, including the election of directors, and does not have cumulative voting rights. Accordingly, the holders of a majority of the shares
of our common stock entitled to vote in any election of directors can elect all of the directors standing for election.
Dividends.
Subject to preferences that may be applicable to any then outstanding preferred stock, the holders of common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available
funds.
Liquidation. In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to
share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any outstanding
shares of preferred stock.
Rights and Preferences. Holders of our common stock have no preemptive, conversion or subscription
rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of
shares of any series of our preferred stock that we may designate and issue in the future.
Fully Paid and Nonassessable. All of
our outstanding shares of common stock are, and any shares of common stock to be issued by us in an offering under this prospectus will be, fully paid and nonassessable.
Preferred Stock
Our board of directors
has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights,
preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such
series then outstanding.
Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could
adversely affect the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have
the effect of delaying, deferring or preventing a change in our control that may otherwise benefit holders of our common stock and may adversely affect the market price of the common stock and the voting and other rights of the holders of common
stock. As of the date of this prospectus, there are no shares of preferred stock outstanding and we have no current plans to issue any shares of preferred stock.
8
Registration Rights
The holders of 1,303,780 shares of common stock, or their transferees, have the right to require us to register their shares with the SEC
following the date of this prospectus so that those shares may be publicly resold, or to include their shares in any registration statement we file on Form S-1 or Form S-3.
Form S-3 Registration Rights. If we are eligible to file a registration statement on Form S-3, one or more holders of registration
rights have the right to demand that we file a registration statement on Form S-3 so long as the aggregate value of the securities to be sold under the registration statement on Form S-3 is at least a specified dollar amount, subject to specified
exceptions.
Piggyback Registration Rights. If we register any securities for public sale, holders of registration
rights will have the right to include their shares in the registration statement. The underwriters of any underwritten offering will have the right to limit the number of shares having registration rights to be included in the registration
statement, subject to specified limitations. We have complied with, or obtained waivers with respect to, any and all rights to have shares registered under this registration statement.
Expenses of Registration. Generally, we are required to bear all registration and selling expenses incurred in connection with the
piggyback and Form S-3 registrations described above, other than underwriting discounts and commissions.
Expiration of Registration
Rights. The piggyback and Form S-3 registration rights discussed above will terminate in February 2018 or at such earlier time as such shares are sold in a public offering pursuant to a registration statement or pursuant to Rule 144 of the
Securities Act.
Anti-takeover Effects of Provisions of our Certificate of Incorporation, our Bylaws and Delaware Law
We are subject to Section 203 of the Delaware General Corporation Law, or Section 203. Section 203 generally prohibits a public
Delaware corporation from engaging in a business combination with an interested stockholder for a period of three years after the date of the transaction in which the person became an interested stockholder, unless:
|
|
|
prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
|
|
|
|
the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding
(a) shares owned by persons who are directors and also officers and (b) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be
tendered in a tender or exchange offer; or |
|
|
|
on or subsequent to the date of the transaction, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of
at least 66 2⁄3% of the outstanding voting stock which is not owned by the interested stockholder.
|
Section 203 defines a business combination to include:
|
|
|
any merger or consolidation involving the corporation and the interested stockholder; |
|
|
|
any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation; |
|
|
|
subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested
stockholder; |
9
|
|
|
subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; and |
|
|
|
the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. |
In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding
voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.
Certificate of
Incorporation and Bylaws
Provisions of our certificate of incorporation and bylaws may delay or discourage transactions involving an
actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares or transactions that our stockholders might otherwise deem to be in their best
interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our certificate of incorporation and bylaws:
|
|
|
permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate (including the right to approve an acquisition or other change in our
control); |
|
|
|
provide that the authorized number of directors may be changed only by resolution of the board of directors; |
|
|
|
provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;
|
|
|
|
require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent; |
|
|
|
provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner
and also specify requirements as to the form and content of a stockholders notice; |
|
|
|
do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election,
if they should so choose); and |
|
|
|
provide that special meetings of our stockholders may be called only by the Chairman of the Board, our Chief Executive Officer or by the board of directors pursuant to a resolution adopted by a majority of the total
number of authorized directors. |
The amendment of any of these provisions, with the exception of the ability of our board of
directors to issue shares of preferred stock and designate any rights, preferences and privileges thereto, would require approval by the holders of at least
66 2⁄3% of our then outstanding common stock.
NASDAQ Global Market Listing
Our common
stock is listed on The NASDAQ Global Market under the RGLS symbol.
Transfer Agent and Registrar
The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. The transfer agent and registrars address is
250 Royall Street, Canton, MA, 02021.
10
SELLING STOCKHOLDER
This prospectus relates to the resale by the selling stockholder named herein of up to 597,833 shares of our common stock. For more
information, see SummaryPrivate Placements above.
In September 2007, we entered into a license and collaboration
agreement with Alnylam and Ionis, which we subsequently amended, restated and superseded in January 2009, and further amended in June 2010, October 2011 and August 2013. Under the agreement, we acquired an exclusive, royalty-bearing, worldwide
license, with rights to sublicense, to patent rights owned or licensed by Alnylam and Ionis to develop, manufacture and commercialize products covered by the licensed patent rights for use in microRNA compounds which are microRNA
antagonists and microRNA therapeutics containing these compounds. In addition, we have certain rights to miR-mimics. Under the agreement, we granted to both Alnylam and Ionis a license to practice our intellectual property developed by us to
the extent that it is useful specifically to Alnylams RNAi programs or Ionis single-stranded oligonucleotide programs, but not including microRNA compounds or therapeutics that are the subject of our exclusive licenses from
Alnylam and Ionis.
We are required to use commercially reasonable efforts to develop and commercialize licensed products under the
agreement. We are required to notify Alnylam and Ionis when a program reaches development stage (defined as initiation of good laboratory practices, or GLP, toxicology studies) and whether or not we intend to pursue the program. Under the agreement,
both Alnylam and Ionis have an option to assume the development and commercialization of product candidates in a program that we do not pursue. If neither Alnylam nor Ionis exercises this option, we are required to use our best efforts to finalize a
term sheet with a third party with respect to such program. In the event we are unable to complete a transaction with a third party, both Alnylam and Ionis have a second opt-in option.
If an election is made by either Alnylam or Ionis (but not both) to opt-in, such party will pay us a one-time fixed payment, the amount of
which will depend on whether the first or the second opt-in option was exercised, with a higher amount due if the first opt-in option was exercised. Clinical and regulatory milestones are also payable to us in the event the opt-in election is
exercised. Such milestones total $64.0 million in the aggregate if the election is made during the first opt-in period or $15.7 million in the aggregate if the election is made at the second opt-in period. Tiered royalties are payable to us as a
percentage of net sales on all products commercialized by the opt-in party. These royalties range from the low to middle single digits depending upon the volume of sales. The opt-in party is also entitled to sublicense the development program to a
third party. In such a case, we are also entitled to receive a percentage of the sublicense income received by the opt-in party. The percentage payable depends upon the point at which the opt-in party sublicenses the program and ranges from the low
end of the 10 to 20% range to the high end of the 40 to 50% range. The opt-in party is only required to pay the higher of the clinical and regulatory milestones or the sublicense income received in any calendar quarter. The opt-in party is also
responsible for all third party payments due under other agreements as a result of the development. In the event both Alnylam and Ionis elect to opt-in during either opt-in period, the parties have agreed to work together to amend the development
plan to continue development of the project, including funding of such project and assignment of roles and responsibilities.
In the event
we or one of our strategic alliance partners continues with the development of a program, each of Alnylam and Ionis are entitled to royalties as a percentage of net sales. For products that we independently commercialize, these royalties will be in
the low single digits. For products commercialized by a third-party collaborator, the royalties will be either the same percentage of net sales as described above or, if the sublicense does not provide a specified level of royalties to us or upon
our election, a percentage of the sublicense income received by us from the strategic alliance partner and a modified royalty. The modified royalty would be based upon the lower of the single digit percentage discussed above or one third of the
royalty received by us after payments made by us to third parties for development, manufacture and commercialization activities under other agreements. In addition, if we sublicense rights to a collaborator, we will be required to pay to each of
Alnylam and Ionis a percentage of our sublicense income in the mid-single digits. We are also responsible for payments due to third parties under other agreements as a result of our development activities, including payments owed by Alnylam and/or
Ionis under their agreements.
11
Under the October 2011 amendment, Alnylam and Ionis granted us the right to research
microRNA mimics under the licensed intellectual property of Alnylam and Ionis. In the event we develop a miR-mimic, we must first obtain approval from Alnylam and/or Ionis, as applicable, and such approval is subject to the consent of
applicable third parties, if any. No additional consideration will be owed by us to Alnylam or Ionis for granting approval. We have the right to sublicense our research rights. We granted to both Alnylam and Ionis a fully paid up, worldwide and
exclusive license to any intellectual property developed by us and useful to their research programs and which are not microRNA antagonists or approved miR-mimics.
In August 2013, we entered into an amendment to the agreement, pursuant to which the parties agreed to our use of certain Alnylam-controlled
intellectual property concerning the use and manufacture of GalNAc conjugates (GalNAc Process Technology) on a non-exclusive basis. We will generally not be permitted to sublicense or otherwise transfer the GalNAc Process Technology and
other Alnylam licensed intellectual property rights relating to GalNAc conjugate technology without the prior written consent of Alnylam, subject to certain limited exceptions for sublicenses to third party collaboration partners. There were no
financial terms related to this amendment.
The agreement expires on the earlier of the cessation of development of the potential
royalty-bearing products prior to the commercial sale of any such products anywhere in the world or following the first commercial sale of such products, the expiration of royalty obligations determined on a country-by-country and product-by-product
basis.
This table below was prepared based on information supplied to us by the selling stockholder and reflects holdings as of January
31, 2016. As used in this prospectus, the term selling stockholder includes the selling stockholder listed below, and any donees, pledges, transferees or other successors in interest selling shares received after the date of this
prospectus from the selling stockholder as a gift, pledge, or other non-sale related transfer. The number of shares in the column Number of Shares Being Offered represents the shares that the selling stockholder may offer under this
prospectus. The selling stockholder may sell some, all or none of its shares. The selling stockholder may, at any time and from time to time, offer and sell pursuant to this prospectus any or all of the shares set forth below in any type of
transaction, as more fully described in the section entitled Plan of Distribution on page [ ]. We do not know how long the selling stockholder will hold the shares before selling them, and we currently have no
agreements, arrangements or understandings with the selling stockholder regarding the sale of any of the shares.
The percentage ownership
information after the offering is based on 52,695,533 shares of our common stock outstanding as of January 31, 2016. Unless otherwise indicated, beneficial ownership is determined in accordance with Section 13(d) of the Exchange Act and the
rules and regulations thereunder, and is based upon information provided by each respective selling stockholder identified below.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name and Address |
|
Shares of Common Stock Beneficially Owned Before Offering |
|
|
Number of Shares Being Offered |
|
|
Shares of Common Stock Beneficially Owned Following the Offering |
|
|
|
|
|
|
|
|
|
Number |
|
|
% of Class |
|
Ionis Pharmaceuticals, Inc. 2855 Gazelle Court Carlsbad, CA 92010 |
|
|
2,843,172 |
|
|
|
597,833 |
|
|
|
2,245,339 |
|
|
|
4.26 |
% |
12
PLAN OF DISTRIBUTION
We or the selling stockholder may sell the common stock from time to time pursuant to underwritten public offerings, direct sales to the
public, negotiated transactions, block trades or a combination of these methods. We or the selling stockholder may sell the common stock to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute
the common stock from time to time in one or more transactions:
|
|
|
from time to time in one or more transactions at a fixed price or prices, which may be changed from time to time; |
|
|
|
at market prices prevailing at the time of sale; |
|
|
|
at prices related to such prevailing market prices; or |
We may also sell equity securities covered by this registration
statement in an at the market offering as defined in Rule 415 under the Securities Act. Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price, either:
|
|
|
on or through the facilities of The Nasdaq Global Market or any other securities exchange or quotation or trading service on which such securities may be listed, quoted or traded at the time of sale; and/or
|
|
|
|
to or through a market maker otherwise than on The Nasdaq Global Market or such other securities exchanges or quotation or trading services. |
Such at-the-market offerings, if any, may be conducted by financial institutions acting as principal or agent.
Any applicable prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be provided to you) will
describe the terms of the offering of the common stock, including, to the extent applicable:
|
|
|
the name or names of the underwriters, if any; |
|
|
|
the purchase price of the common stock or other consideration therefor, and the proceeds, if any, we will receive from the sale; |
|
|
|
any over-allotment options under which underwriters may purchase additional common stock from us; |
|
|
|
any agency fees or underwriting discounts and other items constituting agents or underwriters compensation; |
|
|
|
any public offering price; |
|
|
|
any discounts or concessions allowed or reallowed or paid to dealers; and |
|
|
|
any securities exchange or market on which the common stock may be listed. |
Only underwriters
named in an applicable prospectus supplement will be underwriters of the common stock offered by such prospectus supplement.
If
underwriters are used in the sale, they will acquire the common stock for their own account and may resell the common stock from time to time in one or more transactions at a fixed public offering price or at varying prices determined at the time of
sale. The obligations of the underwriters to purchase the common stock will be subject to the conditions set forth in the applicable underwriting agreement. We or the selling stockholder may offer the common stock to the public through underwriting
syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be
13
obligated to purchase all of the common stock offered by an applicable prospectus supplement, other than common stock covered by any over-allotment option. Any public offering price and any
discounts or concessions allowed or reallowed or paid to dealers may change from time to time. We or the selling stockholder may use underwriters with whom we have a material relationship. We will describe in any applicable prospectus supplement,
naming the underwriter, the nature of any such relationship.
We or the selling stockholder may sell common stock directly or through
agents we designate from time to time. We will name any agent involved in the offering and sale of common stock and we will describe any commissions we or the selling stockholder will pay the agent in an applicable prospectus supplement. Unless any
applicable prospectus supplement states otherwise, our or the selling stockholders agent will act on a best-efforts basis for the period of its appointment.
We or the selling stockholder may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase
common stock from us or the selling stockholder at the public offering price set forth in an applicable prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will
describe the conditions to these contracts and the commissions we or the selling stockholder must pay for solicitation of these contracts in an applicable prospectus supplement.
We or the selling stockholder may provide agents and underwriters with indemnification against civil liabilities, including liabilities under
the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these liabilities. Agents and underwriters may engage in transactions with, or perform services for, us or the selling stockholder
in the ordinary course of business.
Any underwriter may engage in over-allotment, stabilizing transactions, short-covering transactions
and penalty bids in accordance with Regulation M under the Exchange Act. Over-allotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying common stock
so long as the stabilizing bids do not exceed a specified maximum price. Syndicate-covering or other short-covering transactions involve purchases of the common stock, either through exercise of the over-allotment option or in the open market after
the distribution is completed, to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the common stock originally sold by the dealer are purchased in a stabilizing or covering transaction to
cover short positions. Those activities may cause the price of the common stock to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time.
Any underwriters or agents who are qualified market makers on the Nasdaq Global Select Market may engage in passive market making transactions
in our common stock on the Nasdaq Global Select Market in accordance with Rule 103 of Regulation M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the common stock. Passive market
makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such common stock;
if all independent bids are lowered below the passive market makers bid, however, the passive market makers bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the
common stock at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time.
In compliance with guidelines of the Financial Industry Regulatory Authority, or FINRA, the maximum consideration or discount to be received
by any FINRA member or independent broker dealer may not exceed 8% of the aggregate amount of the common stock offered pursuant to this prospectus and any applicable prospectus supplement.
14
LEGAL MATTERS
The validity of the securities offered hereby is being passed upon for us by Cooley LLP, San Diego, California.
EXPERTS
Ernst & Young LLP, independent registered public accounting firm, has audited our financial statements included in our Annual Report on
Form 10-K for the year ended December 31, 2014 as set forth in their report, which is incorporated by reference in this prospectus and elsewhere in the registration statement. Ernst & Young LLP has audited our financial statements at
December 31, 2015 and 2014, and for each of the three years in the period ended December 31, 2015, as set forth in their report included within this prospectus and elsewhere in the registration statement. Our financial statements are
included and incorporated by reference in reliance on Ernst & Young LLPs reports, given on their authority as experts in accounting and auditing.
WHERE YOU CAN FIND MORE INFORMATION
We file reports, proxy statements and other documents with the SEC as required by the Exchange Act. You can find, copy and inspect information
we file at the SECs public reference room at 100 F Street, N.E., Washington, D.C. 20549. You can call the SEC at 1-800-SEC-0330 for further information about the public reference room. You can review our electronically filed reports,
proxy and information statements on the SECs web site at www.sec.gov or on our web site at www.regulusrx.com. Information included on our web site is not part of this prospectus or any prospectus supplement.
This prospectus is part of a registration statement that we filed with the SEC. The registration statement contains more information than this
prospectus regarding us and our common stock, including exhibits and schedules. You can obtain a copy of the registration statement from the SEC at any address listed above or from the SECs web site.
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
The SEC allows us to incorporate into this prospectus information that we file with the SEC in other documents. This means that we
can disclose important information to you by referring to other documents that contain that information. Any information that we incorporate by reference is considered part of this prospectus.
Information contained in this prospectus and information that we file with the SEC in the future and incorporate by reference in this
prospectus automatically modifies and supersedes previously filed information including information in previously filed documents or reports that have been incorporated by reference in this prospectus, to the extent the new information differs from
or is inconsistent with the old information. Any information so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.
We incorporate by reference, as of their respective dates of filing, the documents listed below that we have filed with the SEC and any
documents that we file with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus and prior to the termination of the last offering of common stock under this prospectus (except in each
case the information contained in such documents to the extent furnished and not filed):
|
|
|
our Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on February 19, 2015; |
15
|
|
|
our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2015, June 30, 2015 and September 30, 2015, filed with the SEC on May 8, 2015, August 5, 2015 and November 6, 2015, respectively; |
|
|
|
our Current Reports on Form 8-K filed with the SEC on February 9, 2015, April 7, 2015, June 4, 2015, June 11, 2015, June 26, 2015, November 27, 2015, December 4, 2015, December 8, 2015, January 8, 2016 and
February 17, 2016; |
|
|
|
the information specifically incorporated by reference into our Annual Report on Form 10-K for the year ended December 31, 2014 from our definitive proxy statement on Schedule 14A filed with the SEC on April 30,
2015; and |
|
|
|
the description of our common stock contained in our registration statement on Form 8-A filed with the SEC on September 27, 2012, including any amendment or report filed for the purpose of updating such
description. |
You may also request a copy of these filings, at no cost, by writing us at 3545 John Hopkins Court,
Suite 210, San Diego, California 92121 or telephoning us at (858) 202-6300.
16
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 14. |
Other Expenses of Issuance and Distribution. |
The following table sets forth the various
expenses to be incurred in connection with the registration of the common stock being registered hereby, all of which will be borne by the Registrant. All amounts shown are estimates except the SEC registration fee.
|
|
|
|
|
SEC registration fee |
|
$ |
15,476 |
|
Legal fees and expenses |
|
|
300,000 |
|
Accounting fees and expenses |
|
|
150,000 |
|
Miscellaneous expenses |
|
|
9,524 |
|
|
|
|
|
|
Total expenses |
|
$ |
475,000 |
|
|
|
|
|
|
Item 15. |
Indemnification of Directors and Officers. |
The Registrants certificate of
incorporation and bylaws provide that each person who was or is made a party or is threatened to be made a party to or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of
the fact that he or she is or was one of the Registrants directors or officers or is or was serving at the Registrants request as a director, officer, or trustee of another corporation, or of a partnership, joint venture, trust or other
enterprise, whether the basis of such proceeding is alleged action in an official capacity as a director, officer or trustee or in any other capacity while serving as a director, officer or trustee, shall be indemnified and held harmless by the
Registrant to the fullest extent authorized by the DGCL against all expense, liability and loss (including attorneys fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action.
Section 145 of the DGCL permits a corporation to indemnify any director or officer of the corporation against expenses (including
attorneys fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with any action, suit or proceeding brought by reason of the fact that such person is or was a director or officer of the
corporation, if such person acted in good faith and in a manner that he or she reasonably believed to be in, or not opposed to, the best interests of the corporation, and, with respect to any criminal action or proceeding, if he or she had no reason
to believe his or her conduct was unlawful. In a derivative action, (i.e., one brought by or on behalf of the corporation), indemnification may be provided only for expenses actually and reasonably incurred by any director or officer in
connection with the defense or settlement of such an action or suit if such person acted in good faith and in a manner that he or she reasonably believed to be in, or not opposed to, the best interests of the corporation, except that no
indemnification shall be provided if such person shall have been adjudged to be liable to the corporation, unless and only to the extent that the court in which the action or suit was brought shall determine that the defendant is fairly and
reasonably entitled to indemnity for such expenses despite such adjudication of liability.
Pursuant to Section 102(b)(7) of the
DGCL, the Registrants certificate of incorporation eliminates the liability of a director to the Registrants stockholders for monetary damages for such a breach of fiduciary duty as a director, except for liabilities arising:
|
|
|
from any breach of the directors duty of loyalty to the Registrant or the Registrants stockholders; |
|
|
|
from acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; |
|
|
|
under Section 174 of the DGCL; and |
|
|
|
from any transaction from which the director derived an improper personal benefit. |
II-1
The Registrant has entered into agreements to indemnify the Registrants directors and
executive officers. These agreements, among other things, provide that the Registrant will indemnify the director or executive officer to the fullest extent authorized or permitted by the provisions of the Registrants certificate of
incorporation, bylaws or law for claims arising in his or her capacity as a director or officer of the Registrant. The indemnification agreements also establish the procedures that will apply in the event a director or officer makes a claim for
indemnification.
The Registrant maintains a general liability insurance policy which covers certain liabilities of directors and officers
of the Registrant arising out of claims based on acts or omissions in their capacities as directors or officers.
The foregoing discussion
of the Registrants certificate of incorporation, bylaws, indemnification agreements, and Delaware law is not intended to be exhaustive and is qualified in its entirety by such certificate of incorporation, bylaws, indemnification agreements,
or law.
In any underwriting agreement the Registrant enters into in connection with the sale of common stock being registered hereby, the
underwriters will agree to indemnify, under certain conditions, the Registrant, the Registrants directors, the Registrants officers and persons who control the Registrant with the meaning of the Securities Act of 1933 against certain
liabilities.
See the Exhibit Index on the page immediately preceding the exhibits for a
list of exhibits filed as part of this Registration Statement, which Exhibit Index is incorporated herein by reference.
The undersigned Registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities
offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC
pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the Calculation of Registration Fee table in the
effective Registration Statement.
(iii) To include any material information with respect to the plan of distribution not previously
disclosed in the Registration Statement or any material change to such information in the Registration Statement;
provided, however, that
paragraphs (1)(i), (1)(ii) and (1)(iii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the Registrant pursuant to
Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the Registration Statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the
Registration Statement.
II-2
(2) That, for the purpose of determining any liability under the Securities Act of 1933, each
such post-effective amendment shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering.
(4) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:
(A) Each prospectus filed by the Registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the Registration Statement
as of the date the filed prospectus was deemed part of and included in the Registration Statement; and
(B) Each prospectus required
to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a Registration Statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the
information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the Registration Statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of
the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new
effective date of the Registration Statement relating to the securities in the Registration Statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof. Provided, however, that no statement made in a Registration Statement or prospectus that is part of the Registration Statement or made in a document incorporated or deemed incorporated by reference into the Registration Statement or
prospectus that is part of the Registration Statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the Registration Statement or prospectus that was part of
the Registration Statement or made in any such document immediately prior to such effective date;
(5) That, for the purpose of
determining liability of the Registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned Registrant undertakes that in a primary offering of securities of the undersigned Registrant
pursuant to this Registration Statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned
Registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:
(i) Any
preliminary prospectus or prospectus of the undersigned Registrant relating to the offering required to be filed pursuant to Rule 424;
(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned Registrant or used or referred to
by the undersigned Registrant;
(iii) The portion of any other free writing prospectus relating to the offering containing material
information about the undersigned Registrant or its securities provided by or on behalf of the undersigned Registrant; and
(iv) Any
other communication that is an offer in the offering made by the undersigned Registrant to the purchaser.
(6) The undersigned
Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrants annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of
1934 (and, where applicable, each filing of an employee benefit plans annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the Registration Statement shall be deemed to be a
new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
II-3
(7) That, for purposes of determining any liability under the Securities Act of 1933:
(i) the information omitted from the form of prospectus filed as part of the registration statement in reliance upon Rule 430A and
contained in the form of prospectus filed by the registrant pursuant to Rule 424(b)(l) or (4) or 497(h) under the Securities Act of 1933 shall be deemed to be a part of the registration statement as of the time it was declared effective; and
(ii) each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to
the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore,
unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of
any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.
II-4
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on February
23, 2016.
|
|
|
REGULUS THERAPEUTICS INC. |
|
|
By: |
|
/s/ Paul C. Grint |
|
|
Paul C. Grint, M.D.
President and Chief Executive Officer |
SIGNATURES AND POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Paul C. Grint, M.D. and Joseph P.
Hagan, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all
post-effective amendments to this registration statement and any registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and to file the same, with
all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and
thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or their
or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities
Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
|
|
|
|
|
Signature |
|
Title |
|
Date |
|
|
|
/s/ Paul C. Grint
Paul C. Grint, M.D. |
|
President, Chief Executive Officer and
Member of the Board of Directors
(Principal Executive Officer) |
|
February 23, 2016 |
|
|
|
/s/ Joseph P.
Hagan Joseph P. Hagan |
|
Chief Operating Officer
(Principal Financial and Accounting Officer) |
|
February 23, 2016 |
|
|
|
/s/ David
Baltimore David Baltimore, Ph.D. |
|
Member of the Board of Directors |
|
February 23, 2016 |
|
|
|
/s/ Mark G.
Foletta Mark G. Foletta |
|
Member of the Board of Directors |
|
February 23, 2016 |
|
|
|
/s/ Stelios
Papadopoulos Stelios Papadopoulos, Ph.D. |
|
Member of the Board of Directors |
|
February 23, 2016 |
|
|
|
/s/ William H.
Rastetter William H. Rastetter, Ph.D. |
|
Member of the Board of Directors |
|
February 23, 2016 |
|
|
|
/s/ Douglas E.
Williams Douglas E. Williams, Ph.D. |
|
Member of the Board of Directors |
|
February 23, 2016 |
EXHIBIT INDEX
|
|
|
Exhibit Number |
|
Description |
|
|
1.1 |
|
Form of Underwriting Agreement (to be filed by amendment or as an exhibit to a current report on Form 8-K of the Registrant, and incorporated herein by reference). |
|
|
4.1 |
|
Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrants Current Report on Form 8-K, filed with the SEC on October 11, 2012). |
|
|
4.2 |
|
Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrants Current Report on Form 8-K, filed with the SEC on December 5, 2014). |
|
|
4.3 |
|
Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 to the Registrants Registration Statement on Form S-1, as amended (File No. 333-183384), originally filed with the SEC on
August 17, 2012). |
|
|
4.4 |
|
Registration Rights Agreement dated February 5, 2014 between the Registrant and Aventisub LLC (formerly Aventis Holdings Inc.) (incorporated by reference to Exhibit 99.3 to the Registrants Current Report on Form 8-K, filed
with the SEC on February 5, 2014). |
|
|
5.1 |
|
Opinion of Cooley LLP. |
|
|
23.1 |
|
Consent of Independent Registered Public Accounting Firm. |
|
|
23.2 |
|
Consent of Cooley LLP (included in Exhibit 5.1). |
|
|
24.1 |
|
Power of Attorney (included on signature page). |
|
|
99.1 |
|
Audited Financial Statements at December 31, 2015 and 2014, and for each of the three years in the period ended December 31, 2015. |
Exhibit 5.1
Thomas A. Coll
T: +1 858 550
6013
collta@cooley.com
February 23, 2016
Regulus Therapeutics Inc.
3545 John Hopkins Court, Ste. 210
San Diego, CA 92121
Ladies and Gentlemen:
We represent Regulus Therapeutics Inc., a Delaware corporation (the Company), in connection with its filing of
post-effective amendment no. 1 to a Registration Statement on Form S-3 (the Registration Statement) under the Securities Act of 1933, as amended (the Securities Act), relating to shares of
common stock, par value $0.001 per share (Common Stock), of the Company (the Shares), including, but not limited to, the resale of 597,833 shares of Common Stock held by certain selling
stockholders as described in the Registration Statement (the Resale Shares). The Shares are being registered for offer and sale from time to time pursuant to Rule 415 of the General Rules and Regulations
promulgated under the Securities Act (the Securities Act Rules).
In connection with this opinion, we have
examined and relied upon the originals, or copies certified to our satisfaction, of such records, documents, certificates, opinions, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion
expressed below. As to certain factual matters, we have relied upon certificates of the officers of the Company and have not sought independently to verify such matters.
In rendering this opinion, we have assumed the genuineness and authenticity of all signatures on original documents; the authenticity of all
documents submitted to us as originals; the conformity to originals of all documents submitted to us as copies thereof; and the accuracy, completeness and authenticity of certificates of public officials. We have also assumed that, at the time of
issuance and sale of the Shares, a sufficient number of shares of Common Stock is authorized and reserved or available for issuance and that the consideration for the issuance and sale of such Shares is not less than the par value of the Common
Stock, and that, prior to any offering and sale of the Shares, the Companys board of directors (the Board), including any appropriate committee appointed thereby, will duly authorize the terms of and the prices at
which the Shares are to be issued and sold.
Our opinion herein is expressed solely with respect to the federal laws of the United
States and the Delaware General Corporation Law. We express no opinion to the extent that the laws of any other jurisdiction are applicable to the subject matter hereof. We are not rendering any opinion as to compliance with any federal or state
antifraud law, rule or regulation relating to securities, or to the sale or issuance thereof.
On the basis of the foregoing and in reliance thereon,
and subject to the qualifications herein stated, we are of the opinion that, with respect to any offering of Shares, other than the Resale
4401 Eastgate Mall,
San Diego, CA 92121 T: (858) 550-6000 F: (858) 550-6420 www.cooley.com
February 23, 2016
Page Two
Shares, when (i) the Registration Statement and any required post-effective amendment thereto have become effective; (ii) an appropriate prospectus supplement with respect to such
Shares has been prepared, delivered and filed in compliance with the Securities Act and the applicable Securities Act Rules; (iii) if such Shares are to be sold pursuant to a purchase, underwriting or similar agreement, such purchase,
underwriting or similar agreement has been duly authorized, executed and delivered by the Company and the other parties thereto and has become a valid and binding agreement of the Company; (iv) the Board, including any appropriate committee
appointed thereby, and appropriate officers of the Company have taken all necessary corporate action to approve the issuance and terms of such Shares and related matters; and (v) the terms of such Shares and of their issuance and sale have been
duly established in conformity with the operative certificate of incorporation and bylaws of the Company and the Delaware General Corporation Law so as not to violate any applicable law, the operative certificate of incorporation or bylaws of the
Company or result in a default under or breach of any agreement or instrument binding upon the Company and so as to comply with any requirement or restriction imposed by any court or governmental body having jurisdiction over the Company, then such
Shares will be duly authorized, validly issued, fully paid and nonassessable. The Resale Shares have been validly issued and are fully paid and nonassessable.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference to our firm under the caption Legal
Matters in the prospectus included in the Registration Statement.
Sincerely,
Cooley LLP
|
|
|
|
|
By: |
|
/s/ Thomas A. Coll |
|
|
Thomas A. Coll, Esq. |
4401 Eastgate Mall, San Diego, CA 92121
T: (858) 550-6000 F: (858) 550-6420 www.cooley.com
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption Experts in Amendment No. 1 to the Registration Statement (Form S-3
No. 333-203292) and related Prospectus of Regulus Therapeutics Inc. for the registration of common stock and to the incorporation by reference therein of our report dated February 18, 2015, with respect to the financial statements of
Regulus Therapeutics Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2014, filed with the Securities and Exchange Commission, and to the use of our report dated February 23, 2016, with respect to the
financial statements of Regulus Therapeutics Inc. for the year ended December 31, 2015, included as Exhibit 99.1 to Amendment No. 1 to the Registration Statement (Form S-3 No. 333-203292).
/s/ Ernst & Young LLP
San Diego, California
February 23, 2016
EXHIBIT 99.1
Financial Statements and Supplementary Data
Report of Independent Registered Public Accounting Firm
The Board of Directors and Stockholders of Regulus Therapeutics Inc.
We have audited the accompanying balance sheets of Regulus Therapeutics Inc. as of December 31, 2015 and 2014, and the related statements of operations and
comprehensive loss, stockholders equity, and cash flows for each of the three years in the period ended December 31, 2015. These financial statements are the responsibility of the Companys management. Our responsibility is to express an
opinion on these financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting
Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the
Companys internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of
expressing an opinion on the effectiveness of the Companys internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures
in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Regulus Therapeutics Inc.
at December 31, 2015 and 2014, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2015, in conformity with U.S. generally accepted accounting principles.
San Diego, California
February 23, 2016
1
Regulus Therapeutics Inc.
BALANCE SHEETS
(in
thousands, except share and per share data)
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
|
|
2015 |
|
|
2014 |
|
Assets |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
15,960 |
|
|
$ |
37,327 |
|
Short-term investments |
|
|
98,103 |
|
|
|
122,416 |
|
Restricted cash |
|
|
1,256 |
|
|
|
|
|
Contract and other receivables |
|
|
10,021 |
|
|
|
274 |
|
Prepaid expenses |
|
|
8,159 |
|
|
|
4,192 |
|
Other current assets |
|
|
759 |
|
|
|
742 |
|
|
|
|
|
|
|
|
|
|
Total current assets |
|
|
134,258 |
|
|
|
164,951 |
|
Property and equipment, net |
|
|
5,400 |
|
|
|
3,568 |
|
Intangibles, net |
|
|
1,081 |
|
|
|
1,150 |
|
Other assets |
|
|
344 |
|
|
|
1,811 |
|
|
|
|
|
|
|
|
|
|
Total assets |
|
$ |
141,083 |
|
|
$ |
171,480 |
|
|
|
|
|
|
|
|
|
|
Liabilities and stockholders equity |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
2,717 |
|
|
$ |
2,188 |
|
Accrued liabilities |
|
|
6,329 |
|
|
|
4,402 |
|
Accrued compensation |
|
|
2,392 |
|
|
|
2,108 |
|
Current portion of deferred revenue |
|
|
1,194 |
|
|
|
3,097 |
|
Convertible note payable, at fair value |
|
|
|
|
|
|
23,397 |
|
|
|
|
|
|
|
|
|
|
Total current liabilities |
|
|
12,632 |
|
|
|
35,192 |
|
Deferred revenue, less current portion |
|
|
2,065 |
|
|
|
3,252 |
|
Other long-term liabilities |
|
|
2,308 |
|
|
|
1,022 |
|
|
|
|
|
|
|
|
|
|
Total liabilities |
|
|
17,005 |
|
|
|
39,466 |
|
Commitments and Contingencies (Note 8) |
|
|
|
|
|
|
|
|
Stockholders equity: |
|
|
|
|
|
|
|
|
Common stock, $0.001 par value; 200,000,000 shares authorized, 52,669,266 and 48,944,530 shares issued and outstanding at December 31,
2015 and 2014, respectively |
|
|
53 |
|
|
|
49 |
|
Additional paid-in capital |
|
|
315,673 |
|
|
|
267,929 |
|
Accumulated other comprehensive loss |
|
|
(133 |
) |
|
|
(197 |
) |
Accumulated deficit |
|
|
(191,515 |
) |
|
|
(135,767 |
) |
|
|
|
|
|
|
|
|
|
Total stockholders equity |
|
|
124,078 |
|
|
|
132,014 |
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders equity |
|
$ |
141,083 |
|
|
$ |
171,480 |
|
|
|
|
|
|
|
|
|
|
See accompanying notes to these financial statements.
2
Regulus Therapeutics Inc.
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2015 |
|
|
2014 |
|
|
2013 |
|
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
Revenue under strategic alliances and collaborations |
|
$ |
20,759 |
|
|
$ |
7,669 |
|
|
$ |
19,569 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues |
|
|
20,759 |
|
|
|
7,669 |
|
|
|
19,569 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
56,387 |
|
|
|
41,046 |
|
|
|
29,942 |
|
General and administrative |
|
|
19,130 |
|
|
|
11,533 |
|
|
|
7,429 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses |
|
|
75,517 |
|
|
|
52,579 |
|
|
|
37,371 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations |
|
|
(54,758 |
) |
|
|
(44,910 |
) |
|
|
(17,802 |
) |
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
Interest and other income |
|
|
855 |
|
|
|
388 |
|
|
|
292 |
|
Interest and other expense |
|
|
(52 |
) |
|
|
(39 |
) |
|
|
(36 |
) |
Loss from valuation of convertible note payable |
|
|
(1,811 |
) |
|
|
(12,118 |
) |
|
|
(1,145 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss before income taxes |
|
|
(55,766 |
) |
|
|
(56,679 |
) |
|
|
(18,691 |
) |
Income tax benefit (expense) |
|
|
18 |
|
|
|
(1 |
) |
|
|
23 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(55,748 |
) |
|
$ |
(56,680 |
) |
|
$ |
(18,668 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive loss: |
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized gain (loss) on short-term investments, net |
|
|
64 |
|
|
|
(181 |
) |
|
|
36 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive loss |
|
$ |
(55,684 |
) |
|
$ |
(56,861 |
) |
|
$ |
(18,632 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share, basic and diluted |
|
$ |
(1.08 |
) |
|
$ |
(1.29 |
) |
|
$ |
(0.49 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares used to compute basic and diluted net loss per share |
|
|
51,411,353 |
|
|
|
44,090,165 |
|
|
|
38,479,447 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to these financial statements.
3
STATEMENTS OF STOCKHOLDERS EQUITY
(in thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock |
|
|
Additional paid-in capital |
|
|
Accumulated other comprehensive income (loss) |
|
|
Accumulated deficit |
|
|
Total stockholders equity |
|
|
|
Shares |
|
|
Amount |
|
|
|
|
|
Balance at December 31, 2012 |
|
|
35,831,808 |
|
|
$ |
36 |
|
|
$ |
122,528 |
|
|
$ |
(52 |
) |
|
$ |
(60,419 |
) |
|
$ |
62,093 |
|
Issuance of common stock upon exercise of options |
|
|
732,483 |
|
|
|
1 |
|
|
|
593 |
|
|
|
|
|
|
|
|
|
|
|
594 |
|
Stock-based compensation expense |
|
|
|
|
|
|
|
|
|
|
3,422 |
|
|
|
|
|
|
|
|
|
|
|
3,422 |
|
Issuance of common stock under Employee Stock Purchase Plan |
|
|
48,035 |
|
|
|
|
|
|
|
201 |
|
|
|
|
|
|
|
|
|
|
|
201 |
|
Issuance of common stock, net of $434 of offering costs |
|
|
5,175,000 |
|
|
|
5 |
|
|
|
45,774 |
|
|
|
|
|
|
|
|
|
|
|
45,779 |
|
Unrealized gain on short-term investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
36 |
|
|
|
|
|
|
|
36 |
|
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(18,668 |
) |
|
|
(18,668 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2013 |
|
|
41,787,326 |
|
|
$ |
42 |
|
|
$ |
172,518 |
|
|
$ |
(16 |
) |
|
$ |
(79,087 |
) |
|
$ |
93,457 |
|
Issuance of common stock upon exercise of options |
|
|
1,006,515 |
|
|
|
1 |
|
|
|
2,232 |
|
|
|
|
|
|
|
|
|
|
|
2,233 |
|
Stock-based compensation expense |
|
|
|
|
|
|
|
|
|
|
7,039 |
|
|
|
|
|
|
|
|
|
|
|
7,039 |
|
Issuance of common stock under Employee Stock Purchase Plan |
|
|
38,085 |
|
|
|
|
|
|
|
283 |
|
|
|
|
|
|
|
|
|
|
|
283 |
|
Issuance of common stock in private placement |
|
|
1,303,780 |
|
|
|
1 |
|
|
|
9,568 |
|
|
|
|
|
|
|
|
|
|
|
9,569 |
|
Issuance of common stock, net of $347 of offering costs |
|
|
4,808,824 |
|
|
|
5 |
|
|
|
76,289 |
|
|
|
|
|
|
|
|
|
|
|
76,294 |
|
Unrealized loss on short-term investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(181 |
) |
|
|
|
|
|
|
(181 |
) |
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(56,680 |
) |
|
|
(56,680 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2014 |
|
|
48,944,530 |
|
|
$ |
49 |
|
|
$ |
267,929 |
|
|
$ |
(197 |
) |
|
$ |
(135,767 |
) |
|
$ |
132,014 |
|
Issuance of common stock upon exercise of options |
|
|
2,298,618 |
|
|
|
2 |
|
|
|
6,678 |
|
|
|
|
|
|
|
|
|
|
|
6,680 |
|
Stock-based compensation expense |
|
|
|
|
|
|
|
|
|
|
15,368 |
|
|
|
|
|
|
|
|
|
|
|
15,368 |
|
Issuance of common stock under Employee Stock Purchase Plan |
|
|
69,380 |
|
|
|
|
|
|
|
492 |
|
|
|
|
|
|
|
|
|
|
|
492 |
|
Conversion of convertible note payable into common stock |
|
|
1,356,738 |
|
|
|
2 |
|
|
|
25,206 |
|
|
|
|
|
|
|
|
|
|
|
25,208 |
|
Unrealized gain on short-term investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
64 |
|
|
|
|
|
|
|
64 |
|
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(55,748 |
) |
|
|
(55,748 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2015 |
|
|
52,669,266 |
|
|
$ |
53 |
|
|
$ |
315,673 |
|
|
$ |
(133 |
) |
|
$ |
(191,515 |
) |
|
$ |
124,078 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to these financial statements.
4
Regulus Therapeutics Inc.
STATEMENTS OF CASH FLOWS
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years ended December 31, |
|
|
|
2015 |
|
|
2014 |
|
|
2013 |
|
Operating activities |
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(55,748 |
) |
|
$ |
(56,680 |
) |
|
$ |
(18,668 |
) |
Adjustments to reconcile net loss to net cash used in operating activities |
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization expense |
|
|
1,591 |
|
|
|
1,490 |
|
|
|
1,360 |
|
Loss from valuation of convertible note payable |
|
|
1,811 |
|
|
|
12,118 |
|
|
|
1,145 |
|
Stock-based compensation |
|
|
15,368 |
|
|
|
7,039 |
|
|
|
3,422 |
|
Amortization of premium on investments, net |
|
|
1,472 |
|
|
|
1,597 |
|
|
|
1,439 |
|
Loss on disposal of long-term assets |
|
|
98 |
|
|
|
18 |
|
|
|
|
|
Change in operating assets and liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
Contracts and other receivables |
|
|
(9,746 |
) |
|
|
(196 |
) |
|
|
(79 |
) |
Prepaid expenses |
|
|
(3,967 |
) |
|
|
(1,795 |
) |
|
|
(1,890 |
) |
Other assets |
|
|
(176 |
) |
|
|
(87 |
) |
|
|
(393 |
) |
Accounts payable |
|
|
529 |
|
|
|
940 |
|
|
|
860 |
|
Accrued liabilities |
|
|
2,094 |
|
|
|
556 |
|
|
|
1,355 |
|
Accrued compensation |
|
|
284 |
|
|
|
811 |
|
|
|
(51 |
) |
Deferred revenue |
|
|
(3,090 |
) |
|
|
(5,039 |
) |
|
|
(16,819 |
) |
Deferred rent and other liabilities |
|
|
(379 |
) |
|
|
(282 |
) |
|
|
(11 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in operating activities |
|
|
(49,859 |
) |
|
|
(39,510 |
) |
|
|
(28,330 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Investing activities |
|
|
|
|
|
|
|
|
|
|
|
|
Purchases of short-term investments |
|
|
(78,401 |
) |
|
|
(113,417 |
) |
|
|
(72,005 |
) |
Sales and maturities of short-term investments |
|
|
101,306 |
|
|
|
85,421 |
|
|
|
31,951 |
|
Purchases of property and equipment |
|
|
(1,363 |
) |
|
|
(1,146 |
) |
|
|
(800 |
) |
Acquisition of intangibles |
|
|
(67 |
) |
|
|
(65 |
) |
|
|
(35 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) investing activities |
|
|
21,475 |
|
|
|
(29,207 |
) |
|
|
(40,889 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Financing activities |
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of common stock, net |
|
|
492 |
|
|
|
86,146 |
|
|
|
45,980 |
|
Proceeds from exercise of common stock options |
|
|
6,680 |
|
|
|
2,233 |
|
|
|
594 |
|
Principal payments on other long-term obligations |
|
|
(155 |
) |
|
|
(142 |
) |
|
|
(100 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by financing activities |
|
|
7,017 |
|
|
|
88,237 |
|
|
|
46,474 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (decrease) increase in cash and cash equivalents |
|
|
(21,367 |
) |
|
|
19,520 |
|
|
|
(22,745 |
) |
Cash and cash equivalents at beginning of period |
|
|
37,327 |
|
|
|
17,807 |
|
|
|
40,552 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of period |
|
$ |
15,960 |
|
|
$ |
37,327 |
|
|
$ |
17,807 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure of cash flow information |
|
|
|
|
|
|
|
|
|
|
|
|
Net changes in restricted cash |
|
$ |
1,256 |
|
|
$ |
|
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest paid |
|
$ |
(27 |
) |
|
$ |
(39 |
) |
|
$ |
(37 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Income taxes paid |
|
$ |
(1 |
) |
|
$ |
(1 |
) |
|
$ |
(1 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure of non-cash investing and financing activities |
|
|
|
|
|
|
|
|
|
|
|
|
Allowance for tenant improvements |
|
$ |
1,656 |
|
|
$ |
|
|
|
$ |
653 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amounts accrued for property and equipment |
|
$ |
223 |
|
|
$ |
76 |
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amounts accrued for patent expenditures |
|
$ |
28 |
|
|
$ |
42 |
|
|
$ |
11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to these financial statements.
5
Regulus Therapeutics Inc.
NOTES TO FINANCIAL STATEMENTS
(Unaudited)
1. The Business, Basis of
Presentation and Summary of Significant Accounting Policies
Regulus Therapeutics Inc. was originally formed as a Delaware limited
liability company under the name Regulus Therapeutics LLC on September 6, 2007, when Alnylam Pharmaceuticals, Inc. (Alnylam) and Ionis Pharmaceuticals, Inc., (Ionis) (formerly, Isis Pharmaceuticals, Inc.), contributed
significant intellectual property, know-how and financial and human capital to pursue the development of drugs targeting microRNAs pursuant to a license and collaboration agreement. Regulus Therapeutics Inc. was converted to a Delaware
corporation on January 2, 2009. As used herein, unless the context suggests otherwise, the Company, our, us and we means Regulus Therapeutics Inc.
Use of Estimates
Our financial
statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our
financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates
are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.
Revenue Recognition
Our revenues
generally consist of upfront payments for licenses or options to obtain licenses in the future, milestone payments and payments for other research services under strategic alliance and collaboration agreements. We recognize revenues when all four of
the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery of the products and/or services has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured.
Multiple element arrangements, such as our strategic alliance agreements with Sanofi and AstraZeneca AB (AstraZeneca) and our
collaboration agreement with Biogen Inc. (Biogen), formerly Biogen Idec MA Inc., are analyzed to determine whether the deliverables within the agreement can be separated or whether they must be accounted for as a single unit of
accounting. Deliverables under the agreement will be accounted for as separate units of accounting provided that (i) a delivered item has value to the customer on a stand-alone basis; and (ii) if the agreement includes a general right of
return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially in the control of the vendor. The allocation of consideration amongst the deliverables under the agreement is derived
using a best estimate of selling price if vendor specific objective evidence and third-party evidence of fair value is not available. If the delivered element does not have stand-alone value, the arrangement is then accounted for as a
single unit of accounting, and we recognize the consideration received under the arrangement as revenue on a straight-line basis, which approximates effort over our estimated period of performance, which for us is often the expected term of the
research and development plan.
Milestones
We apply the milestone method of accounting to recognize revenue from milestone payments when earned, as evidenced by written acknowledgement
from the collaborator or other persuasive evidence that the milestone has been achieved and the payment is non-refundable, provided that the milestone event is substantive. A milestone event is defined as an event (i) that can only be achieved
based in whole or in part on either our performance or on the occurrence of a specific outcome resulting from our performance; (ii) for which there is substantive uncertainty at the inception of the arrangement that the event will be achieved;
and (iii) that would result in additional payments being due to us. Events for which the occurrence is either contingent solely upon the passage of time or the result of a counterpartys performance are not considered to be milestone
events. A milestone event is substantive if all of the following conditions are met: (i) the consideration is commensurate with either our performance to achieve the milestone, or the enhancement of the value to the delivered item(s) as a
result of a
6
specific outcome resulting from our performance to achieve the milestone; (ii) the consideration relates solely to past performance; and (iii) the consideration is reasonable relative
to all the deliverables and payment terms (including other potential milestone consideration) within the arrangement.
We assess whether a
milestone is substantive at the inception of each arrangement. If a milestone is deemed non-substantive, we will account for that milestone payment using a method consistent with the related units of accounting for the arrangement over the related
performance period.
Deferred Revenue
Amounts received prior to satisfying the above revenue recognition criteria are recorded as deferred revenue in the accompanying balance
sheets. Amounts not expected to be recognized within the next 12 months are classified as non-current deferred revenue.
Stock-Based Compensation
We account for stock-based compensation expense related to stock options granted to employees and members of our board of directors by
estimating the fair value of each stock option on the date of grant using the Black-Scholes option pricing model. We recognize stock-based compensation expense using the accelerated multiple-option approach. Under the accelerated multiple-option
approach (also known as the graded-vesting method), we recognize compensation expense over the requisite service period for each separately vesting tranche of the award as though the award was in substance multiple awards, resulting in accelerated
expense recognition over the vesting period. For performance-based awards granted to employees (i) the fair value of the award is determined on the grant date, (ii) we assess the probability of the individual milestones under the award
being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.
We account for stock options granted to non-employees using the fair value approach. Stock options granted to non-employees are subject to
periodic revaluation over their vesting terms.
Research and Development
Research and development costs are expensed as incurred and consist of costs associated with research activities supporting our drug discovery
efforts, compensation and related benefits, non-cash stock-based compensation, license fees, laboratory supplies and associated overhead and facility costs. In certain circumstances, we make non-refundable advance payments to purchase goods and
services for future use in research and development activities pursuant to contractual arrangements. In those instances, we capitalize these amounts and record expense in the period that we receive the goods or when services are performed.
Income Taxes
Income taxes are accounted
for under the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of the differences between the tax basis of assets or liabilities and their carrying
amounts in the financial statements using the enacted tax rates and laws that are anticipated to be in effect when the differences are expected to reverse. We provide a valuation allowance against net deferred tax assets if it is more likely than
not that these items will either expire before the Company is able to realize their benefit or if future deductibility is uncertain.
In
accordance with the accounting standards for uncertain tax positions, the Company evaluates the recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of tax positions taken or expected to be
taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities.
7
Fair Value Option
Applicable accounting policies permit entities to choose, at specified election dates, to measure specified items at fair value if the decision
about the election is: (1) applied instrument by instrument, (2) irrevocable, and (3) applied to an entire instrument. The balance of our convertible note payable, which was valued under the fair value option, was converted into shares of common
stock in January 2015 (see Note 4).
Clinical Trial and Pre-Clinical Study Accruals
We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on the facts and circumstances known
to us at that time. Our accrued expenses for pre-clinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by clinical trial investigational sites, clinical research
organizations (CROs) and for other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial
milestones. In accruing for these services, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If possible, we obtain information regarding unbilled services directly from these
service providers. However, we may be required to estimate these services based on other information available to us. If we underestimate or overestimate the activities or fees associated with a study or service at a given point in time, adjustments
to research and development expenses may be necessary in future periods. Historically, our estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in our accruals.
Cash and Cash Equivalents
We classify
time deposits and other investments that are highly liquid and have maturities of 90 days or less at the date of purchase as cash equivalents. The carrying amounts approximate fair value due to the short maturities of these instruments.
Restricted Cash
Restricted cash consists
of amounts received for a specific and limited purpose, and therefore not available for general operating activities. In August 2015, we received $1.4 million in connection with our facility lease agreement with Walton Torrey Owner B, L.L.C,
entered into in July 2015. The use of these funds are restricted to costs associated with the relocation of our corporate headquarters. As of December 31, 2015, our restricted cash balance was approximately $1.3 million.
Short-Term Investments
We carry
short-term investments classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. Our short-term investments consist of both Level 1 and Level 2 financial instruments in the
fair value hierarchy. We record unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders equity. We determine the realized
gains or losses of available-for-sale securities using the specific identification method and include net realized gains and losses in interest income.
At each balance sheet date, we assess available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is
other-than-temporary. We consider factors including: the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market
value of the security has been less than its cost basis, the securitys relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. When we determine that a decline in the fair
value below its cost basis is other-than-temporary, we recognize an impairment loss in the year in which the other-than-temporary decline occurred. We determined that there were no other-than-temporary declines in the value of short-term investments
as of December 31, 2015 or 2014.
Concentrations of Credit Risk
Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash equivalents and
short-term investments. We maintain deposits in federally insured financial institutions in excess of federally
8
insured limits. We have not experienced any losses in such accounts and believe we are not exposed to significant risk. We maintain our cash equivalents and short-term investments with three
financial institutions. We invest our excess cash primarily in commercial paper, certificates of deposit and debt instruments of financial institutions and corporations. Additionally, we adhere to established guidelines regarding approved
investments and maturities of investments, which are designed to preserve their principal value and maintain liquidity.
Property and Equipment
We carry our property and equipment at cost, which consists of lab equipment, computer equipment and software, furniture and fixtures
and leasehold improvements. Property and equipment is depreciated using the straight-line method over the estimated useful lives (generally three to five years). Leasehold improvements are amortized over the lesser of their useful life or the
remaining lease term, including any renewal periods that are deemed to be reasonably assured. Repair and maintenance costs that do not improve service potential or extend economic life are expensed as incurred.
Intangibles
We capitalize costs which
consist principally of outside legal costs and filing fees related to obtaining patents. We review our capitalized patent costs periodically to determine that they include costs for patent applications that have future value and an alternative
future use. We evaluate costs related to patents that we are not actively pursuing and write off these costs. We amortize patent costs over their patent lives, beginning with the date the patents are issued. The weighted average remaining life of
the issued patents was approximately 11 years at December 31, 2015.
We obtain licenses from third parties and capitalize the costs
related to exclusive licenses that have alternative future use within multiple potential programs. We amortize capitalized licenses over their estimated useful life or term of the agreement, which for current licenses is 10 years.
Impairment of Long-Lived Assets
We
regularly review the carrying amount of our property, equipment and intangible assets to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. If indications of impairment exist,
projected future undiscounted cash flows associated with the asset are compared to the carrying amount to determine whether the assets value is recoverable. If the carrying value of the asset exceeds such projected undiscounted cash flows, the
asset will be written down to its estimated fair value. No impairment charges were recorded during the years ended December 31, 2015, 2014 or 2013.
Segment Reporting
Operating segments are
identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, we
have viewed our operations and managed our business as one segment operating primarily within the United States.
Comprehensive Loss
Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non-owner
sources. Our only component of other comprehensive loss is unrealized gains (losses) on available-for-sale securities. Comprehensive gains (losses) have been reflected in the statements of operations and comprehensive loss and as a separate
component in the statements of stockholders equity for all periods presented.
Recent Accounting Pronouncements
In May 2014, the FASB issued ASU No. 2014-9, Revenue from Contracts with Customers (ASU 2014-19). Adoption of ASU
No. 2014-9 requires that an entity recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This
update is effective for annual reporting periods beginning after December 15, 2017 and interim periods therein and requires expanded disclosures. We are currently evaluating the impact of adoption on our financial statements.
9
In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements
Going Concern, which requires management to assess an entitys ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. This standard is effective for annual reporting periods ending after
December 15, 2016 and interim periods thereafter. Early application is permitted. The adoption of this guidance will have no impact on our financial statements.
In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes, which requires that deferred tax
liabilities and assets be classified as non-current in the balance sheet. This standard is effective for annual reporting periods beginning after December 15, 2016, and interim periods within those annual periods. The Company has elected
to adopt this ASU prospectively, as is permitted under the standard. The adoption of this standard did not have a material impact on our financial statements for the year ended December 31, 2015 and will not have a material impact in future years.
In January 2016, the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities, which
eliminates the requirement for public companies to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance
sheet. Additionally, the standard requires public entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes. Furthermore, the standard requires presentation of financial assets and
liabilities by measurement category and form of financial asset on the balance sheet or accompanying notes to the financial statements. The standard is effective for fiscal years beginning after December 15, 2017, including interim periods
within those fiscal years. We are currently evaluating the impact of adoption on our financial statements.
2. Net Loss Per Share
Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding for the period,
without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method.
Dilutive common stock equivalents are comprised of options outstanding under our stock option plans and convertible note payable, which was converted into common stock in January 2015. For all periods presented, there is no difference in the
number of shares used to calculate basic and diluted net loss per share.
Potentially dilutive securities not included in the calculation
of diluted net loss per share because to do so would be anti-dilutive are as follows (in common equivalent shares):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years ended December 31, |
|
|
|
2015 |
|
|
2014 |
|
|
2013 |
|
Common stock options |
|
|
1,674,119 |
|
|
|
2,566,423 |
|
|
|
3,639,270 |
|
Convertible note payable |
|
|
|
|
|
|
1,461,474 |
|
|
|
1,411,659 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
1,674,119 |
|
|
|
4,027,897 |
|
|
|
5,050,929 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3. Investments
We invest our excess cash in commercial paper and debt instruments of financial institutions and corporations. As of December 31, 2015,
our short-term investments had a weighted average maturity of less than two years.
10
The following tables summarize our short-term investments (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maturity (in years) |
|
|
Amortized cost |
|
|
Unrealized |
|
|
Estimated fair value |
|
|
|
|
Gains |
|
|
Losses |
|
|
As of December 31, 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corporate debt securities |
|
|
2 or less |
|
|
$ |
81,054 |
|
|
$ |
16 |
|
|
$ |
(103 |
) |
|
$ |
80,967 |
|
Certificates of deposit |
|
|
2 or less |
|
|
|
13,640 |
|
|
|
|
|
|
|
|
|
|
|
13,640 |
|
Commercial paper |
|
|
1 or less |
|
|
|
3,490 |
|
|
|
6 |
|
|
|
|
|
|
|
3,496 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
|
|
|
$ |
98,184 |
|
|
$ |
22 |
|
|
$ |
(103 |
) |
|
$ |
98,103 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maturity (in years) |
|
|
Amortized cost |
|
|
Unrealized |
|
|
Estimated fair value |
|
|
|
|
Gains |
|
|
Losses |
|
|
As of December 31, 2014 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corporate debt securities |
|
|
2 or less |
|
|
$ |
105,085 |
|
|
$ |
2 |
|
|
$ |
(167 |
) |
|
$ |
104,920 |
|
Certificates of deposit |
|
|
2 or less |
|
|
|
14,600 |
|
|
|
|
|
|
|
|
|
|
|
14,600 |
|
Commercial paper |
|
|
1 or less |
|
|
|
2,895 |
|
|
|
1 |
|
|
|
|
|
|
|
2,896 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
|
|
|
$ |
122,580 |
|
|
$ |
3 |
|
|
$ |
(167 |
) |
|
$ |
122,416 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4. Fair Value Measurements
We have certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2, or 3 within the fair value
hierarchy as described in the accounting standards for fair value measurements.
Accounting standards define fair value as the exchange
price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date.
Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The accounting standards provide an established hierarchy for
inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants
would use in valuing the asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors that market participants would use in valuing the
asset or liability. The accounting standards prioritize the inputs used in measuring the fair value into the following hierarchy:
|
|
|
Level 1 includes financial instruments for which quoted market prices for identical instruments are available in active markets. |
|
|
|
Level 2 includes financial instruments for which there are inputs other than quoted prices included within Level 1 that are observable for the instrument such as quoted prices for similar instruments in active markets,
quoted prices for identical or similar instruments in markets with insufficient volume or infrequent transactions (less active markets) or model-driven valuations in which significant inputs are observable or can be derived principally from, or
corroborated by, observable market data. |
|
|
|
Level 3 includes financial instruments for which fair value is derived from valuation techniques in which one or more significant inputs are unobservable, including managements own assumptions. |
11
The following table presents our fair value hierarchy for assets and liabilities measured at fair
value on a recurring basis as of December 31, 2015 and December 31, 2014 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value as of December 31, 2015 |
|
|
|
Total |
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
Assets: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash equivalents |
|
$ |
15,152 |
|
|
$ |
15,152 |
|
|
$ |
|
|
|
$ |
|
|
Corporate debt securities |
|
|
80,967 |
|
|
|
|
|
|
|
80,967 |
|
|
|
|
|
Certificates of deposit |
|
|
13,640 |
|
|
|
|
|
|
|
13,640 |
|
|
|
|
|
Commercial paper |
|
|
3,496 |
|
|
|
|
|
|
|
3,496 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
113,255 |
|
|
$ |
15,152 |
|
|
$ |
98,103 |
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value as of December 31, 2014 |
|
|
|
Total |
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
Assets: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash equivalents |
|
$ |
37,072 |
|
|
$ |
37,072 |
|
|
$ |
|
|
|
$ |
|
|
Corporate debt securities |
|
|
104,920 |
|
|
|
|
|
|
|
104,920 |
|
|
|
|
|
Certificates of deposit |
|
|
14,600 |
|
|
|
|
|
|
|
14,600 |
|
|
|
|
|
Commercial paper |
|
|
2,896 |
|
|
|
|
|
|
|
2,896 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
159,488 |
|
|
$ |
37,072 |
|
|
$ |
122,416 |
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible note payable |
|
$ |
23,397 |
|
|
$ |
|
|
|
$ |
|
|
|
$ |
23,397 |
|
We obtain pricing information from quoted market prices or quotes from brokers/dealers. We generally determine
the fair value of our investment securities using standard observable inputs, including reported trades, broker/dealer quotes, bids and/or offers. Refer to Note 3 for information regarding our investments.
The following table presents a reconciliation of the liability measured at fair value using significant unobservable inputs (Level 3) from
December 31, 2014 to December 31, 2015 (in thousands):
|
|
|
|
|
|
|
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) |
|
Balance at December 31, 2014 |
|
$ |
23,397 |
|
Change in estimated fair value of convertible note payable |
|
|
1,811 |
|
Convertible note converted to shares of common stock |
|
|
(25,208 |
) |
|
|
|
|
|
Balance at December 31, 2015 |
|
$ |
|
|
|
|
|
|
|
We used an income approach in the form of a convertible bond valuation model to value the convertible note
payable. The convertible bond model considered the debt and option characteristics of the note. The key inputs to the model as of December 31, 2014 were volatility of 110%, risk-free rate of 0.10% and credit spread of 9.7%. The volatility
inputs were based on historical and implied volatility of peer companies. Peer companies were materially consistent with those used to determine volatility for stock-based compensation. Beginning in 2014, our historical volatility was included with
the peer companies for purposes of estimating volatility. As of December 31, 2014, the volatility input included 60% weighting of our historical volatility and 40% weighting of historical and implied volatility of peer companies. The risk-free
rate inputs were based on the yield of U.S. Treasury Strips as of each date. The credit spread inputs were based on an analysis of our creditworthiness and market rates for comparable straight debt instruments. On January 29, 2015, the
principal balance of the convertible note payable was converted into 1,356,738 shares of common stock, at a conversion price of $4.00 per share. A final valuation upon conversion at January 29, 2015 was performed, considering only the option
characteristics of the note as its conversion was certain. Key inputs of volatility, risk-free rate and credit spread were considered, however, the final valuation was substantially driven by the number of shares of common stock issued upon
conversion (1,356,738) and our stock price on the date of conversion ($18.58). Upon issuance of the common stock, the fair value of the convertible note was classified into stockholders equity.
12
We recorded a loss from the change in valuation of the convertible note payable of $1.8 million,
$12.1 million and $1.1 million on the statements of operations and comprehensive loss for the years ended December 31, 2015, 2014 and 2013, respectively.
5. Strategic Alliances and Collaborations
The following table summarizes our total revenues from our strategic alliances and collaborations during the periods presented (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year ended December 31, |
|
|
|
2015 |
|
|
2014 |
|
|
2013 |
|
AstraZeneca |
|
$ |
18,871 |
|
|
$ |
1,859 |
|
|
$ |
1,859 |
|
Sanofi |
|
|
71 |
|
|
|
979 |
|
|
|
15,336 |
|
GSK |
|
|
|
|
|
|
3,509 |
|
|
|
1,778 |
|
Biogen |
|
|
1,817 |
|
|
|
1,122 |
|
|
|
596 |
|
Other |
|
|
|
|
|
|
200 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
20,759 |
|
|
$ |
7,669 |
|
|
$ |
19,569 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AstraZeneca
In August 2012, we entered into a collaboration and license agreement with AstraZeneca. Under the terms of the agreement, we have agreed to
collaborate with AstraZeneca to identify, research and develop compounds targeting three microRNA alliance targets primarily in the fields of cardiovascular diseases, metabolic diseases and oncology. Pursuant to the agreement, we granted
AstraZeneca an exclusive, worldwide license to thereafter develop, manufacture and commercialize lead compounds designated by AstraZeneca in the course of the collaboration activities against the alliance targets for all human therapeutic uses.
Under the terms of the agreement we are required to use commercially reasonable efforts to perform all research, development and manufacturing activities described in the research plan, at our cost, until the acceptance of an IND or the end of the
research term, which extends until the fourth anniversary of the date of the agreement, and may be extended only by mutual written agreement of us and AstraZeneca. Following the earlier to occur of the acceptance of an IND in a major market or the
end of the research term, AstraZeneca will assume all costs, responsibilities and obligations for further development, manufacture and commercialization of alliance product candidates.
Under the terms of the agreement, we received an upfront payment of $3.0 million in October 2012. We determined the elements within the
agreement should be treated as a single unit of accounting because the delivered element, the license, does not have stand-alone value. As a result, we are recognizing revenue related to the upfront payment on a straight-line basis over our
estimated period of performance, which is four years based on the expected term of the research and development plan.
Concurrently with
the collaboration and license agreement, we entered into a Common Stock Purchase Agreement (CSPA) with AstraZeneca, pursuant to which we agreed to sell to AstraZeneca an aggregate of $25.0 million of our common stock in a private
placement concurrently with our initial public offering, at a price per share equal to the initial public offering price. In October 2012, in accordance with the CSPA, we sold AstraZeneca 6,250,000 shares of our common stock at a price per share of
$4.00. Further, the CSPA stipulated that AstraZeneca could not sell, transfer, make any short sale of, or grant any option for the sale of any common stock for a 365-day period following the effective date of our initial public offering. Accounting
standards for multiple element arrangements contains a presumption that separate contracts negotiated and/or entered into at or near the same time with the same entity were negotiated as a package and should be evaluated as a single agreement. We
valued the discount applied to the shares of common stock due to the one-year restriction. Based upon restricted stock studies of similar duration and a Black-Scholes valuation to measure a discount for lack of marketability, $4.3 million was
attributed to the collaboration and license agreement. We continue to recognize the $4.3 million into revenue ratably over the estimated period of performance of the collaboration. As of December 31, 2015, deferred revenue associated with the
collaboration and license agreement and CSPA was $1.1 million, which we are expecting to recognize over the remaining contractual term and corresponding estimated period of performance of less than one year.
13
In March 2015, we earned a $2.5 million preclinical milestone payment upon AstraZenecas
selection of RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107, as a lead compound under the agreement. In December 2015, we earned a $10.0 million clinical milestone payment upon AstraZenecas first patient dosing in
a first-in-human Phase I clinical study of RG-125. If all three targets are successfully developed and commercialized through pre-agreed sales targets, we could receive additional milestone payments of up to $485.5 million, including preclinical
milestones of up to $2.5 million upon selection of a lead compound, up to $113.0 million for clinical milestones, and up to $370.0 million for commercialization milestones. In addition, we are entitled to receive royalties based on a percentage of
net sales which will range from the mid-single digits to the low end of the 10 to 20% range, depending upon the product and the volume of sales, which royalties may be reduced in certain, limited circumstances.
We have evaluated the contingent event-based payments under our collaboration and license agreement with AstraZeneca and determined that the
preclinical payments and the milestone earned for the initiation of a Phase I clinical trial meet the definition of substantive milestones. Accordingly, revenue for these achievements will be recognized in its entirety in the period when the
milestone is achieved and collectability is reasonably assured. Other contingent event-based payments under the agreement for which payment is contingent upon the results of AstraZenecas performance will not be accounted for using the
milestone method. Such payments will be recognized as revenue over the remaining estimated period of performance, if any, and when collectability is reasonably assured.
In January 2015, we entered into a letter agreement with AstraZeneca to amend the collaboration and license agreement. Under the terms of the
letter agreement, we agreed to perform additional miR-103/107 program research and development activities related to RG-125. AstraZeneca agreed to fund 50% of the costs for these additional activities, as outlined in the letter agreement. In
accordance with the collaboration and license agreement, AstraZeneca funded 100% of the costs for product manufacturing activities outlined in the letter agreement necessary to support a Phase I clinical study. In December 2015, the
Companys technology was transferred by us to AstraZeneca. Upon completion of the technology transfer, we have no further obligation and AstraZeneca will be responsible for all future development of RG-125. As of December 31, 2015,
the Companys obligations under the letter agreement were substantially complete. We recognized $4.5 million for the year ended 2015 for the performance of research and development and product manufacturing activities outlined in the
letter agreement and the deferred revenue balance as of December 31, 2015 was insignificant.
Sanofi
In July 2012, we amended and restated our collaboration and license agreement with Sanofi to expand the potential therapeutic applications of
the microRNA alliance targets to be developed under such agreement. We determined that the elements within the strategic alliance agreement with Sanofi should be treated as a single unit of accounting because the delivered elements did not
have stand-alone value to Sanofi. The following elements were delivered as part of the strategic alliance with Sanofi: (1) a license for up to four microRNA targets; and (2) a research license under our technology alliance.
In June 2013, the original research term expired, upon which we and Sanofi entered into an option agreement pursuant to which Sanofi was
granted an exclusive right to negotiate the co-development and commercialization of certain of our unencumbered microRNA programs and we were granted the exclusive right to negotiate with Sanofi for co-development and commercialization of
certain miR-21 anti-miRs in oncology and Alport syndrome. In July 2013, we received an upfront payment of $2.5 million, of which $1.25 million is creditable against future amounts payable by Sanofi to us under any future co-development and
commercialization agreement we enter pursuant to the option agreement. Revenue associated with the creditable portion of this option payment remained deferred as of December 31, 2015, and will remain deferred until its application to a
creditable transaction. The non-creditable portion of this payment, $1.25 million, was recognized as revenue over the option period from the effective date of the option agreement in June 2013 through the expiration of the option period in January
2014.
In conjunction with the option agreement, we agreed to continue specified research on the miR-21 programs during the option period.
We re-evaluated our remaining estimated period of performance from the original research term through the term of the option agreement and amortized the remaining deferred revenue of $10.1 million associated with the initial $25.0 million upfront
payment from June 2013 through the expiration of the option period in January 2014.
14
In February 2014, we and Sanofi entered into a second amended and restated collaboration and
license agreement (the 2014 Sanofi Amendment) to renew our strategic alliance to discover, develop and commercialize microRNA therapeutics to focus on specific orphan disease and oncology targets. Under the terms of our renewed
alliance, Sanofi will have opt-in rights to our preclinical fibrosis program targeting miR-21 for the treatment of Alport syndrome, our preclinical program targeting miR-21 for oncology indications, and our preclinical program targeting miR-221/222
for hepatocellular carcinoma (HCC). We are responsible for developing each of these programs to proof-of-concept, at which time Sanofi has an exclusive option on each program. If Sanofi chooses to exercise its option on any of these
programs, Sanofi will reimburse us for a significant portion of our preclinical and clinical development costs and will also pay us an option exercise fee for any such program, provided that $1.25 million of the $2.5 million upfront option fee paid
to us by Sanofi in connection with the June 2013 option agreement will be creditable against such option exercise fee. In addition, we will be eligible to receive clinical and regulatory milestone payments and potentially commercial milestone
payments for these programs. We also continue to be eligible to receive royalties on microRNA therapeutic products commercialized by Sanofi and will have the right to co-promote these products.
In connection with the 2014 Sanofi Amendment, we entered into a Common Stock Purchase Agreement (the Purchase Agreement), pursuant
to which we sold 1,303,780 shares of our common stock to Aventisub LLC (formerly Aventis Holdings, Inc.) (Aventis), an entity affiliated with Sanofi, in a private placement at a price per share of $7.67 for an aggregate purchase price of
$10.0 million. Under the terms of the Purchase Agreement, Aventis was not permitted to sell, transfer, make any short sale of, or grant any option for the sale of any common stock for the 12-month period following its effective date. The Purchase
Agreement and the 2014 Sanofi Amendment were negotiated concurrently and were therefore evaluated as a single agreement. Based upon restricted stock studies of similar duration and a Black-Scholes valuation to measure the discount for lack of
marketability, approximately $0.4 million of the proceeds from the Purchase Agreement was attributed to the 2014 Sanofi Amendment, and represents consideration for the value of the program targeting miR-221/222 for HCC. As this element does not have
stand-alone value, we are recognizing the $0.4 million allocated consideration into revenue ratably over the estimated period of performance of the miR-221/222 program. As of December 31, 2015, deferred revenue associated with the Purchase
Agreement and the 2014 Sanofi Amendment was $0.3 million, which we are expecting to recognize over the remaining estimated period of performance of approximately four years.
We are eligible to receive milestone payments of up to $101.8 million for proof-of-concept option exercise fees (net of $1.25 million
creditable, as noted above), $15.0 million for clinical milestones and up to $300.0 million for regulatory and commercial milestones. In addition, we are entitled to receive royalties based on a percentage of net sales of any products from the
miR-21 and miR-221/222 programs which, in the case of sales in the United States, will be in the middle of the 10 to 20% range, and, in the case of sales outside of the United States, will range from the low end to the middle of the 10 to 20% range,
depending upon the volume of sales. If we exercise our option to co-promote a product, we will continue to be eligible to receive royalties on net sales of each product in the United States at the same rate, unless we elect to share a portion of
Sanofis profits from sales of such product in the United States in lieu of royalties.
We have evaluated the contingent event-based
payments under the 2014 Sanofi Amendment and determined that the proof-of-concept option exercise fees and clinical milestone payments meet the definition of substantive milestones. Accordingly, revenue for these achievements will be recognized in
their entirety in the period when the milestone is achieved and collectability is reasonably assured. Other contingent event-based payments under the 2014 Sanofi Amendment for which payment is contingent upon the results of Sanofis performance
will not be accounted for using the milestone method. Such payments will be recognized as revenue over the remaining estimated period of performance, if any, and when collectability is reasonably assured.
GSK
In April 2008, we entered into a
strategic alliance with GSK to discover, develop and commercialize novel microRNA-targeted therapeutics to treat inflammatory diseases (the immuno-inflammatory alliance). In February 2010, we and GSK expanded the strategic
alliance to include hepatitis C virus infection (HCV) to discover, develop and commercialize microRNA therapeutics targeting miR-122 for the treatment of HCV (the HCV alliance). In June 2012, we amended our
15
immuno-inflammatory alliance to extend the target selection period for the fourth collaboration target. We determined that the elements within the immuno-inflammatory alliance should be treated
as a single unit of accounting because the delivered elements, the opt-in licenses for microRNA product candidates, did not have stand-alone value to GSK. As a result of the extension of the target selection period, we extended the
amortization period for the remaining deferred revenue to approximately eight years, which represented our new estimated period of performance.
In June 2013, the HCV alliance was amended to state that RG-101, and other formulations thereof, will be developed by us independently of our
alliance for the treatment of HCV. This amendment removed any further milestone or royalty obligations owed by GSK to us as it relates to RG-101. Concurrently with the amendment, we recorded the remaining $1.1 million in deferred revenue
associated with the upfront payment from the HCV alliance, as our estimated period of performance was complete.
In October 2014, we
received written notice from GSK of its election to terminate the product development and commercialization agreement. Concurrently with the notice of termination, we recorded the remaining $3.1 million in deferred revenue associated with the
upfront payment, as our estimated period of performance was complete. The effective date of the termination was January 15, 2015.
Biogen
In August 2012, we entered into a collaboration and license agreement with Biogen pursuant to which we and Biogen agreed to collaborate on
microRNA biomarkers for multiple sclerosis (MS). Under the terms of the agreement, in August 2012 we received an upfront payment of $0.8 million. We were also eligible to receive research milestone payments of up to an aggregate
of $1.3 million. We considered the elements within the collaboration and license agreement as a single unit of accounting because the delivered element, the license, did not have stand-alone value. As a result, we recognized revenue relating to the
upfront payment of $0.8 million on a straight-line basis over our estimated period of performance, which was approximately two years based on the expected term of the research and development plan.
In June 2013, we amended the collaboration and license agreement to provide for revised terms with respect to the initial phase of the
research plan and related milestone payment provisions. The amendment did not modify the maximum dollar amount we were originally eligible to receive in connection with the agreement, or our estimated period of performance. In October 2013 and
November 2013, we received research milestone payments totaling $0.3 million under the August 2012 collaboration and license agreement.
In August 2014, we entered into a new collaboration and license agreement with Biogen to collaborate on microRNA biomarkers for MS and
simultaneously executed an agreement terminating the August 2012 collaboration and license agreement. As a result of the termination agreement, we recognized $0.1 million in deferred revenue associated with the upfront payment, as our estimated
period of performance was complete. Pursuant to the terms of the August 2014 collaboration and license agreement, we received an upfront payment of $2.0 million. We determined that the elements within the August 2014 collaboration and license
agreement were to be treated as a single unit of accounting because the delivered element, the license, did not have stand-alone value to Biogen. As a result, we recognized revenue relating to the upfront payment of $2.0 million on a straight-line
basis over the estimated period of performance, which was approximately one year based on the expected term of the research and development plan.
In July 2015, the collaboration and license agreement was amended to modify the conditions of the third research-based
milestone. Additionally, the amendment extended the expected research term from 12 months to 14 months. We recognized the remaining upfront payment on a straight-line basis over the amended expected term. As of September 30, 2015, our period of
performance was complete and the deferred revenue balance was zero.
In January 2015, May 2015, and September 2015, we earned research
milestone payments under the August 2014 collaboration and license agreement of $0.1 million, $0.3 million and $0.3 million, respectively. We have evaluated the contingent event-based payments under our collaboration and license agreement with
Biogen and determined that the research milestone payments met the definition of substantive milestones. Accordingly, revenue for these achievements was recognized in the period the milestones were achieved and collectability was reasonably assured.
16
6. Property and Equipment, net
The following table summarizes our major classes of property and equipment (in thousands):
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
|
|
2015 |
|
|
2014 |
|
Laboratory equipment |
|
$ |
7,310 |
|
|
$ |
6,394 |
|
Computer equipment and software |
|
|
305 |
|
|
|
266 |
|
Furniture and fixtures |
|
|
138 |
|
|
|
119 |
|
Leasehold improvements |
|
|
1,930 |
|
|
|
1,899 |
|
Construction in progress |
|
|
2,167 |
|
|
|
43 |
|
|
|
|
|
|
|
|
|
|
|
|
|
11,850 |
|
|
|
8,721 |
|
Less accumulated depreciation and amortization |
|
|
(6,450 |
) |
|
|
(5,153 |
) |
|
|
|
|
|
|
|
|
|
Property and equipment, net |
|
$ |
5,400 |
|
|
$ |
3,568 |
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization of property and equipment of $1.5 million, $1.4 million and $1.3 million was
recorded for the years ended December 31, 2015, 2014 and 2013, respectively.
7. Intangible Assets, net
The following table summarizes our major classes of intangible assets (in thousands):
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
|
|
2015 |
|
|
2014 |
|
Patents |
|
$ |
1,081 |
|
|
$ |
1,067 |
|
Licenses |
|
|
379 |
|
|
|
379 |
|
|
|
|
|
|
|
|
|
|
|
|
|
1,460 |
|
|
|
1,446 |
|
Accumulated amortization |
|
|
(379 |
) |
|
|
(296 |
) |
|
|
|
|
|
|
|
|
|
Intangibles, net |
|
$ |
1,081 |
|
|
$ |
1,150 |
|
|
|
|
|
|
|
|
|
|
Intangible asset amortization of $0.1 million was recorded for each of the years ended December 31, 2015,
2014 and 2013, respectively. Amortization of these intangible assets over the next five years is expected to be approximately $0.1 million per year.
8. Commitments and Contingencies
Operating Lease
We lease office and laboratory space located in San Diego, California, for our corporate headquarters and research facility under an
operating lease agreement (the Lease). The Lease commenced in July 2010 and provided office and laboratory space, expiring in June 2017.
In connection with the inception of the Lease, we were provided tenant incentives of $0.1 million which was used to construct a leasehold
improvement. In addition, we were provided and fully utilized a tenant improvement allowance of approximately $0.6 million, which was used to fund additional leasehold improvements. In January 2011, the Lease was amended to memorialize the payback
of the allowance into our base rent. In conjunction with the amendment of the Lease in November 2012 to increase rented space by 7,500 square feet, we were provided an additional tenant improvement allowance of approximately $0.7 million, which was
utilized in 2013 to fund leasehold improvements in the newly occupied space. We are obligated to repay our landlord the tenant improvement allowance, plus interest at a fixed rate of 8%, on a monthly basis over the remaining term of the Lease.
17
The Lease provided for early termination rights after the 60th month of the lease, provided at
least 9 months prior written notice however, no early termination rights were available for the additional space occupied in conjunction with the amendment of the Lease in November 2012.
In October 2015, we provided written notice to our landlord of our election to early terminate the Lease. The effective date of
termination for the Lease is June 30, 2016. The additional space occupied in conjunction with the amendment of the Lease in November 2012 expires in June 2017. Termination fees associated with the early termination of the Lease are not
material.
Rent expense under the Lease for the years ended December 31, 2015, 2014 and 2013 was approximately $0.6 million, $0.7
million and $0.7 million, respectively. We account for the difference between the minimum lease payments and the straight-line amount as deferred rent. Deferred rent under the Lease, which is included in other long-term liabilities, at
December 31, 2015 and 2014 was approximately $0.4 million and $0.7 million, respectively. The tenant incentive obligation balance under the Lease at December 31, 2015 and 2014 was approximately $0.3 million and $0.6 million, respectively.
We also pay property taxes, maintenance and insurance, which are expensed as incurred.
In July 2015, we entered into a new lease
agreement for the lease of approximately 59,000 square feet of office and laboratory space in San Diego, California, for a term of 96 months from the lease commencement date, and anticipate moving the Companys headquarters into this new space
in the first half of 2016. In conjunction with the new lease agreement, we received $1.4 million from our landlord in August 2015 for assistance with costs associated with the relocation of our corporate headquarters. These funds were
received for a specific and limited purpose, and therefore are classified as restricted cash and tenant incentive obligation on the Companys balance sheet. As of December 31, 2015, the Company has used approximately $0.1 million for
qualified purposes. In addition, the new lease agreement provided a tenant improvement allowance of up to $8.5 million, which may be used for non-structural leasehold improvements at the new facility. As of December 31, 2015 we have used
approximately $1.7 million of the tenant improvement allowance, which is classified as construction in process and deferred rent on the Companys balance sheet and will be amortized against rent expense on a straight line basis over the term of
the lease, commencing upon lease inception.
The future minimum payment summary below includes amounts payable over the remaining period
of the Lease and the new lease agreement entered into in July 2015.
As of December 31, 2015, aggregate future annual minimum lease
payments for our operating leases are as follows (in thousands):
|
|
|
|
|
2016 |
|
$ |
1,699 |
|
2017 |
|
|
2,330 |
|
2018 |
|
|
2,575 |
|
2019 |
|
|
2,654 |
|
2020 |
|
|
2,733 |
|
Thereafter |
|
|
9,707 |
|
|
|
|
|
|
|
|
$ |
21,698 |
|
License Agreements
We have license agreements with third parties that require us to make annual license maintenance payments and future payments upon the success
of licensed products that include milestones and/or royalties. Minimum future payments over the next five years are not material.
9. Convertible Note
Payable
In October 2012, in conjunction with our initial public offering the Post-IPO GSK Note was established in the principal amount
of $5.4 million, with a maturity date of October 9, 2015. At December 31, 2014, the fair value of the Post-IPO GSK
18
Note was $23.4 million and was classified as Convertible note payable, at fair value on the balance sheet. On January 29, 2015, the principal amount outstanding under the
Post-IPO GSK Note of $5.4 million was converted into 1,356,738 shares of our common stock at a conversion price of $4.00 per share.
10. Common Stock
and Stockholders Equity
Common Stock
As of December 31, 2015, there were 52,669,266 shares of common stock outstanding. Each share of common stock is entitled to one vote. The
holders of the common stock are also entitled to receive dividends whenever funds are legally available and when declared by our Board of Directors.
Shares Reserved for Future Issuance
The
following shares of common stock were reserved for future issuance as of December 31, 2015:
|
|
|
|
|
Common stock options outstanding |
|
|
5,125,667 |
|
Common stock available for future grant under the 2012 Plan |
|
|
1,549,163 |
|
Common stock available for future grant under the Inducement Plan |
|
|
958,052 |
|
Employee Stock Purchase Plan |
|
|
1,260,136 |
|
|
|
|
|
|
Total common shares reserved for future issuance |
|
|
8,893,018 |
|
|
|
|
|
|
The following table summarizes our stock option activity under all equity incentive plans for the year ended
December 31, 2015 (shares and aggregate intrinsic value in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of options |
|
|
Weighted average exercise price |
|
|
Weighted average remaining contractual term |
|
|
Aggregate intrinsic value |
|
Options outstanding at December 31, 2014 |
|
|
6,643 |
|
|
$ |
6.95 |
|
|
|
|
|
|
|
|
|
Granted |
|
|
1,915 |
|
|
$ |
10.98 |
|
|
|
|
|
|
|
|
|
Exercised |
|
|
(2,299 |
) |
|
$ |
2.95 |
|
|
|
|
|
|
|
|
|
Canceled/forfeited/expired |
|
|
(1,133 |
) |
|
$ |
13.13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options outstanding at December 31, 2015 |
|
|
5,126 |
|
|
$ |
8.91 |
|
|
|
7.6 |
|
|
$ |
8,461 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vested or expected to vest at December 31, 2015 |
|
|
4,911 |
|
|
$ |
8.83 |
|
|
|
7.6 |
|
|
$ |
8,319 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercisable at December 31, 2015 |
|
|
1,963 |
|
|
$ |
6.37 |
|
|
|
5.3 |
|
|
$ |
5,816 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The weighted average grant date fair value per share of employee stock options granted during the years ended
December 31, 2015, 2014 and 2013 was $7.47, $8.37 and $4.14, respectively.
The total intrinsic value of stock options exercised was
$21.4 million, $12.1 million and $5.7 million during the years ended December 31, 2015, 2014 and 2013, respectively. Cash received from the exercise of stock options was approximately $6.7 million, $2.2 million and $0.6 million for the years
ended December 31, 2015, 2014 and 2013, respectively.
19
Stock-Based Compensation
The following table summarizes the weighted average assumptions used to estimate the fair value of stock options and performance stock awards
granted to employees under our 2012 Plan and Inducement Plan and the shares purchasable under our 2012 Employee Stock Purchase Plan during the periods presented:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year ended December 31, |
|
|
|
2015 |
|
|
2014 |
|
|
2013 |
|
Stock options |
|
|
|
|
|
|
|
|
|
|
|
|
Risk-free interest rate |
|
|
1.8 |
% |
|
|
1.8 |
% |
|
|
1.9 |
% |
Volatility |
|
|
78.9 |
% |
|
|
74.3 |
% |
|
|
72.4 |
% |
Dividend yield |
|
|
|
|
|
|
|
|
|
|
|
|
Expected term (years) |
|
|
6.1 |
|
|
|
6.1 |
|
|
|
6.1 |
|
Performance stock options |
|
|
|
|
Risk-free interest rate |
|
|
1.8 |
% |
|
|
2.1 |
% |
|
|
|
% |
Volatility |
|
|
76.7 |
% |
|
|
69.6 |
% |
|
|
|
% |
Dividend yield |
|
|
|
|
|
|
|
|
|
|
|
|
Expected term (years) |
|
|
6.0 |
|
|
|
6.3 |
|
|
|
0.0 |
|
Employee stock purchase plan shares |
|
|
|
|
Risk-free interest rate |
|
|
0.1 |
% |
|
|
0.1 |
% |
|
|
0.1 |
% |
Volatility |
|
|
76.1 |
% |
|
|
69.8 |
% |
|
|
58.8 |
% |
Dividend yield |
|
|
|
|
|
|
|
|
|
|
|
|
Expected term (years) |
|
|
0.5 |
|
|
|
0.5 |
|
|
|
0.5 |
|
Risk-free interest rate - The risk-free interest rate assumption was based on observed interest rates appropriate for
the expected term of the stock option grants.
Expected dividend yield - The expected dividend yield assumption was based on the fact that we have
never paid cash dividends and have no present intention to pay cash dividends.
Expected volatility - The expected volatility assumption for the
year ended December 31, 2015 was based on the historical volatility of the trading price of our common stock. The expected volatility assumption for the year ended December 31, 2014 was based on a combination of volatility of a peer group
of similar companies whose share prices were publicly available and the historical volatility of the trading price of our common stock. The expected volatility assumption for the year ended December 31, 2013 was based on volatility of a
peer group of similar companies whose share prices are publicly available and the historical volatility of the trading price of our common stock. The peer group was developed based on companies in the biotechnology industry.
Expected term - The expected term represents the period of time that options are expected to be outstanding. Because we do not have sufficient
historical exercise behavior data, we determine the expected life using the simplified method, which was an average of the contractual term of the option and its ordinary vesting period.
Forfeitures - We reduce stock-based compensation expense for estimated forfeitures. Forfeitures are estimated at the time of grant based upon
historical information and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Our estimated forfeiture rates ranged from 3% to 8% for the years ended December 31, 2015 and 2014.
The following table summarizes the allocation of our stock-based compensation expense for all stock awards during the periods presented (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year ended December 31, |
|
|
|
2015 |
|
|
2014 |
|
|
2013 |
|
Research and development |
|
$ |
8,075 |
|
|
$ |
3,939 |
|
|
$ |
2,246 |
|
General and administrative |
|
|
7,293 |
|
|
|
3,100 |
|
|
|
1,176 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
15,368 |
|
|
$ |
7,039 |
|
|
$ |
3,422 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The total compensation cost related to non-vested awards not yet recognized was $12.4 million as of
December 31, 2015. The weighted-average period over which this expense is expected to be recognized is approximately 1.6 years. For the year ended December 31, 2015, stock-based compensation included $3.9 million in severance charges
associated with the termination of former executives.
20
Employee Stock Purchase Plan
In October 2012, we adopted the 2012 Employee Stock Purchase Plan (2012 Purchase Plan), which enables participants to contribute up
to 15% of such participants eligible compensation during a defined six-month period to purchase our common stock. The purchase price of common stock under the 2012 Purchase Plan will be the lesser of: (i) 85% of the fair market value
of our common stock at the inception of the enrollment period or (ii) 85% of the fair market value of our common stock at the applicable purchase date. We issued 69,380 shares of common stock under the 2012 Purchase Plan for the year ended
December 31, 2015. As of December 31, 2015, 155,500 shares of our common stock were issued and 1,260,136 shares of our common stock were reserved for future issuance and have been authorized for purchase under the 2012 Purchase Plan.
Inducement Plan
On July 17, 2015, the
Companys Board of Directors adopted an Inducement Plan, which became effective immediately. Stockholder approval of the Inducement Plan was not required pursuant to Rule 5635 (c)(4) of the NASDAQ Listing Rules. The Inducement Plan initially
reserved 1,000,000 shares of common stock and provides for the grant of NSOs that will be used exclusively for grants to individuals that were not previously employees or directors of the Company, as an inducement material to the individuals
entry into employment with the Company. Under the Inducement Plan, options may be granted with different vesting terms from time to time, but not to exceed ten years from the date of grant.
Under the Inducement Plan, options typically vest over four years, with 25% of the total grant vesting on the first anniversary of the
effective date of the option grant and the remaining grant vesting monthly thereafter over the following 36 months.
11. Defined Contribution Plan
In 2009, we established an employee 401(k) salary deferral plan (401(k) Plan) covering all eligible employees. Active
employees who are at least 18 years old and are not otherwise disqualified under the terms of the 401(k) Plan are eligible to participate. Employees may contribute up to 50% of their compensation per year (subject to a maximum limit prescribed by
federal tax law). Under the 401(k) Plan, we may elect to match a discretionary percentage of employee contributions. We have elected to match 25% of employees contributions up to 6% of the employees eligible salary. We made $0.1 million
in matching contributions for each of the years ended December 31, 2015, 2014 and 2013, respectively.
12. Income Taxes
The following table summarizes the components of our income tax (benefit) expense (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year ended December 31, |
|
|
|
2015 |
|
|
2014 |
|
|
2013 |
|
Current: |
|
|
|
|
|
|
|
|
|
|
|
|
Federal |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
State |
|
|
1 |
|
|
|
1 |
|
|
|
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 |
|
|
|
1 |
|
|
|
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred: |
|
|
|
|
|
|
|
|
|
|
|
|
Federal |
|
|
(17 |
) |
|
|
|
|
|
|
(20 |
) |
State |
|
|
(2 |
) |
|
|
|
|
|
|
(4 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(19 |
) |
|
|
|
|
|
|
(24 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax (benefit) expense |
|
$ |
(18 |
) |
|
$ |
1 |
|
|
$ |
(23 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
21
The following is a reconciliation of the expected statutory federal income tax provision to our
actual income tax provision (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year ended December 31, |
|
|
|
2015 |
|
|
2014 |
|
|
2013 |
|
Expected income tax benefit at federal statutory tax rate |
|
$ |
(18,960 |
) |
|
$ |
(19,271 |
) |
|
$ |
(6,355 |
) |
State income taxes, net of federal benefit |
|
|
(1,580 |
) |
|
|
(2,348 |
) |
|
|
(1,090 |
) |
Tax credits |
|
|
(5,039 |
) |
|
|
(3,307 |
) |
|
|
(2,406 |
) |
Change in fair value of convertible note payable |
|
|
616 |
|
|
|
4,120 |
|
|
|
456 |
|
Change in valuation allowance |
|
|
23,216 |
|
|
|
20,047 |
|
|
|
9,026 |
|
Prior year true-up |
|
|
110 |
|
|
|
(92 |
) |
|
|
(235 |
) |
Stock compensation |
|
|
1,161 |
|
|
|
902 |
|
|
|
667 |
|
Reserve for uncertain tax positions |
|
|
254 |
|
|
|
|
|
|
|
|
|
Other |
|
|
204 |
|
|
|
(50 |
) |
|
|
(86 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax (benefit) expense |
|
$ |
(18 |
) |
|
$ |
1 |
|
|
$ |
(23 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
The following table summarizes the significant components of our deferred tax assets and liabilities (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
|
|
2015 |
|
|
2014 |
|
Deferred tax assets: |
|
|
|
|
|
|
|
|
Net operating loss carryovers |
|
$ |
48,912 |
|
|
$ |
34,954 |
|
Research and development and other tax credits |
|
|
15,148 |
|
|
|
8,732 |
|
Deferred revenue |
|
|
1,210 |
|
|
|
1,919 |
|
Intangibles and property and equipment basis difference |
|
|
2,097 |
|
|
|
1,874 |
|
Stock compensation expense |
|
|
3,488 |
|
|
|
1,999 |
|
Other |
|
|
1,129 |
|
|
|
617 |
|
|
|
|
|
|
|
|
|
|
Total deferred tax assets |
|
|
71,984 |
|
|
|
50,095 |
|
Total deferred tax liabilities |
|
|
(343 |
) |
|
|
(1,670 |
) |
|
|
|
|
|
|
|
|
|
Net deferred tax asset |
|
|
71,641 |
|
|
|
48,425 |
|
Valuation allowance |
|
|
(71,641 |
) |
|
|
(48,425 |
) |
|
|
|
|
|
|
|
|
|
Net deferred tax asset |
|
$ |
|
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
For all periods presented, we have determined that it is more likely than not that our deferred tax asset will
not be realized. Accordingly, we have recorded a valuation allowance to fully offset the net deferred tax asset of $71.6 million.
As of
December 31, 2015, we had federal and California tax net operating loss carryforwards of $143.5 million and $133.3 million, respectively, which begin to expire in 2030 and 2031. At December 31, 2015, approximately $19.4 million and $14.5
million of the Federal and State net operating loss carryforwards, respectively, relate to stock option exercises, which will
22
result in an increase to additional paid-in capital and a decrease in income taxes payable at the time when the tax loss carryforwards are utilized. As of December 31, 2015, we also had
federal and California research and development tax credit carryforwards of $12.8 million and $5.4 million, respectively. The federal research and development tax credit carryforwards will begin to expire in 2029. The California research and
development tax credit carryforwards are available indefinitely. As of December 31, 2015, we also had $0.2 million of Federal Alternative Minimum Tax Credit carryforwards that are available indefinitely.
The future utilization of our research and development credit carryforwards and net operating loss carryforwards to offset future taxable
income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. The Tax Reform Act of 1986 (the Act) limits a companys ability to utilize certain tax credit carryforwards
and net operating loss carryforwards in the event of a cumulative change in ownerships in excess of 50% as defined in the Act.
The
following table summarizes the changes in the amount of our unrecognized tax benefits (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, |
|
|
|
2015 |
|
|
2014 |
|
|
2013 |
|
Beginning balance of unrecognized tax benefits |
|
$ |
1,853 |
|
|
$ |
1,092 |
|
|
$ |
569 |
|
(Decrease) increase for prior year tax positions |
|
|
(250 |
) |
|
|
(73 |
) |
|
|
137 |
|
Increase for current year tax positions |
|
|
695 |
|
|
|
834 |
|
|
|
386 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
2,298 |
|
|
$ |
1,853 |
|
|
$ |
1,092 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Included in unrecognized tax benefits of $2.3 million at December 31, 2015 was $1.7 million of tax benefits
that, if recognized, would reduce our annual effective tax rate, subject to valuation allowance.
We are subject to taxation in the United
States and California. Our tax years for 2009 and forward are subject to examination by the U.S. tax authorities and our tax years for 2009 and forward are subject to examination by the California tax authorities due to carryforward of unutilized
net operating losses and research and development credits.
It is our practice to recognize interest and/or penalties related to income
tax matters in income tax expense. For the years ended December 31, 2015, 2014 and 2013, we have not recognized any interest or penalties related to income taxes.
13. Related Party Transactions
We have
entered into several agreements with related parties in the ordinary course of business to license intellectual property and to procure administrative and research and development support services.
In September 2014, we entered into an agreement with Sanofi-Aventis Deutschland GmbH (Sanofi Deutschland), a contract
manufacturing subsidiary of Sanofi, for the manufacture of certain drug substance requirements and other services to support our preclinical and clinical activities associated with the RG-012 program. Pursuant to this agreement, we may engage Sanofi
Deutschland from time-to-time to manufacture RG-012 drug product on our behalf. Expenses incurred under the Sanofi agreement for services performed or out-of-pocket expenses were $0.4 million for the year ended December 31, 2015 and zero for
the years ended December 31, 2014 and 2013.
In February 2015, we entered into a letter agreement with Alnylam Pharmaceuticals, Inc.
(Alnylam) pursuant to which we and Alnylam agreed to the financial terms for certain technology acquired by Alnylam within the licensed patent rights under our Amended and Restated License and Collaboration Agreement (the
Additional Patent Rights) with Alnylam and Ionis. In addition to any royalties payable by us to Alnylam pursuant to the terms of the Amended and Restated License and Collaboration Agreement, we agreed to pay Alnylam an additional low
single-digit royalty on net sales of certain products utilizing the Additional Patent Rights, with the exact royalty percentage payable being dependent on the total amount of net sales during the calendar year. We also agreed to pay Alnylam
milestone payments on certain products utilizing the additional patent rights of up to $33.0 million per product upon the achievement of certain regulatory milestone events. There was no activity under this agreement for the year ended
December 31, 2015.
23
14. Selected Quarterly Financial Data (Unaudited)
The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair
statement of the results of the interim periods. Summarized quarterly data for 2015 and 2014 are as follows (in thousands, except per share data):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the quarters ending |
|
|
|
March 31 |
|
|
June 30 |
|
|
September 30 |
|
|
December 31 |
|
2015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues |
|
$ |
4,200 |
|
|
$ |
3,834 |
|
|
$ |
1,865 |
|
|
$ |
10,860 |
|
Operating expenses |
|
|
17,071 |
|
|
|
25,015 |
|
|
|
15,210 |
|
|
|
18,221 |
|
Net loss |
|
|
(14,487 |
) |
|
|
(21,035 |
) |
|
|
(13,000 |
) |
|
|
(7,226 |
) |
Basic and diluted net loss per share(1) |
|
$ |
(0.29 |
) |
|
$ |
(0.41 |
) |
|
$ |
(0.25 |
) |
|
$ |
(0.14 |
) |
2014 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues |
|
$ |
1,631 |
|
|
$ |
736 |
|
|
$ |
1,083 |
|
|
$ |
4,219 |
|
Operating expenses |
|
|
12,336 |
|
|
|
13,749 |
|
|
|
12,742 |
|
|
|
13,752 |
|
Net loss |
|
|
(12,741 |
) |
|
|
(11,973 |
) |
|
|
(9,798 |
) |
|
|
(22,168 |
) |
Basic net loss per share(1) |
|
$ |
(0.30 |
) |
|
$ |
(0.28 |
) |
|
$ |
(0.23 |
) |
|
$ |
(0.47 |
) |
Diluted net loss per share(1)(2) |
|
$ |
(0.30 |
) |
|
$ |
(0.29 |
) |
|
$ |
(0.26 |
) |
|
$ |
(0.47 |
) |
(1) |
Net loss per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly per-share calculations will not necessarily equal the annual per share calculation. |
(2) |
Applicable accounting standards provides that a contract (such as the Post-IPO GSK Note) that is reported as an asset or liability for accounting purposes may require an adjustment to the numerator of the diluted
earnings per share calculation for any changes in income or loss that would result if the contract had been reported as an equity instrument during the period. For these periods, adjustments were made to the numerator of the diluted earnings
per share calculation to adjust net loss to remove the gain from the change in value of the convertible note payable. Adjustments to the denominator were made to add the number of shares to be issued upon conversion of the convertible note
payable. |
24
Regulus Therapeutics (NASDAQ:RGLS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regulus Therapeutics (NASDAQ:RGLS)
Historical Stock Chart
From Jul 2023 to Jul 2024